<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7694078</article-id><article-id pub-id-type="pmid">33114724</article-id><article-id pub-id-type="doi">10.3390/ph13110343</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-13-00343</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>M&#x00101;nuka Oil&#x02014;A Review of Antimicrobial and Other Medicinal Properties</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mathew</surname><given-names>Cynthia</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-13-00343">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7208-2330</contrib-id><name><surname>Tesfaye</surname><given-names>Wubshet</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-13-00343">1</xref></contrib><contrib contrib-type="author"><name><surname>Rasmussen</surname><given-names>Phil</given-names></name><xref ref-type="aff" rid="af2-pharmaceuticals-13-00343">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6764-3882</contrib-id><name><surname>Peterson</surname><given-names>Gregory M</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-13-00343">1</xref><xref ref-type="aff" rid="af3-pharmaceuticals-13-00343">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9095-8460</contrib-id><name><surname>Bartholomaeus</surname><given-names>Andrew</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-13-00343">1</xref><xref ref-type="aff" rid="af4-pharmaceuticals-13-00343">4</xref></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Manab</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-13-00343">1</xref></contrib><contrib contrib-type="author"><name><surname>Thomas</surname><given-names>Jackson</given-names></name><xref ref-type="aff" rid="af1-pharmaceuticals-13-00343">1</xref><xref rid="c1-pharmaceuticals-13-00343" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceuticals-13-00343"><label>1</label>Faculty of Health, University of Canberra, Canberra 2617, Australia; <email>Cynthia.Mathew@canberra.edu.au</email> (C.M.); <email>Wubshet.Tesfaye@canberra.edu.au</email> (W.T.); <email>g.peterson@utas.edu.au</email> (G.M.P.); <email>a.bartholomaeus@uq.edu.au</email> (A.B.); <email>Manab.Sharma@canberra.edu.au</email> (M.S.)</aff><aff id="af2-pharmaceuticals-13-00343"><label>2</label>Phytomed Medicinal Herbs Ltd., Auckland 1026, New Zealand; <email>hil@phytomed.co.nz</email></aff><aff id="af3-pharmaceuticals-13-00343"><label>3</label>Tasmanian School of Pharmacy, University of Tasmania, Hobart 7001, Australia</aff><aff id="af4-pharmaceuticals-13-00343"><label>4</label>Faculty of Medicine, University of Queensland, Brisbane 4072, Australia</aff><author-notes><corresp id="c1-pharmaceuticals-13-00343"><label>*</label>Correspondence: <email>jackson.thomas@canberra.edu.au</email></corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>10</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2020</year></pub-date><volume>13</volume><issue>11</issue><elocation-id>343</elocation-id><history><date date-type="received"><day>14</day><month>9</month><year>2020</year></date><date date-type="accepted"><day>09</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>M&#x00101;nuka oil is an essential oil derived from <italic>Leptospermum scoparium</italic>, a plant that has been used by the indigenous populations of New Zealand and Australia for centuries. Both the extracted oil and its individual components have been associated with various medicinal properties. Given the rise in resistance to conventional antibiotics, natural products have been targeted for the development of antimicrobials with novel mechanism of action. This review aimed to collate available evidence on the antimicrobial, anti-parasitic and anti-inflammatory activities of m&#x00101;nuka oil and its components. A comprehensive literature search of was conducted using PubMed and Embase (via Scopus) targeting articles from database inception until June 2020. Chemical structures and IUPAC names were sourced from PubChem. Unpublished information from grey literature databases, Google search, targeted websites and Google Patents were also included. The present review found extensive in vitro data supporting the antimicrobial effects of m&#x00101;nuka oil warrants further clinical studies to establish its therapeutic potential. Clinical evidence on its efficacy, safety and dosing guidelines are necessary for its implementation for medical purposes. Further work on regulation, standardization and characterization of the medicinal properties of m&#x00101;nuka oil is required for establishing consistent efficacy of the product.</p></abstract><kwd-group><kwd>m&#x00101;nuka oil</kwd><kwd><italic>Leptospermum scoparium</italic></kwd><kwd>antimicrobial</kwd><kwd>antibacterial</kwd><kwd>antiparasitic</kwd><kwd>medicinal</kwd><kwd>therapeutic properties</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-13-00343"><title>1. Introduction</title><p>M&#x00101;nuka (<italic>Leptospermum scoparium</italic>), also known as kahikatoa, red m&#x00101;nuka and tea tree, belongs to the <italic>Myrtaceae</italic> plant family and is found throughout New Zealand and Australia [<xref rid="B1-pharmaceuticals-13-00343" ref-type="bibr">1</xref>]. Commonly grouped under &#x02018;tea trees,&#x02019; which also includes <italic>Camellia sinensis, Kunzea ericoides</italic>, <italic>Leptospermum petersonii</italic> and <italic>Melaleuca alternifolia</italic>, these species have been used by the M&#x00101;ori, the Aboriginals and early European settlers as topical preparations for wounds, cuts, sores and skin diseases and as inhalations for colds and fevers. Interest in the medicinal properties of m&#x00101;nuka, particularly m&#x00101;nuka honey, has grown over the last 30 years. There is also a growing interest in the volatile oil due to its potential application as a medicinal agent or cosmetic ingredient [<xref rid="B2-pharmaceuticals-13-00343" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-13-00343" ref-type="bibr">3</xref>]. Currently, there has not been a critical review on the efficacy and potential applications of m&#x00101;nuka oil while there have been extensive reviews on M&#x00101;nuka honey and its medical applications. We aim to bridge this gap through this review, providing an up-to-date summary of recent developments in our understanding of the medicinal activities of m&#x00101;nuka oil as well as its clinical efficacy&#x02014;and toxicity profile.</p></sec><sec id="sec2-pharmaceuticals-13-00343"><title>2. Search Strategy</title><p>Literature search was conducted using PubMed and Embase (via Scopus) targeting articles from database inception until June 2020. Key terms like &#x02018;<italic>Leptospermum scoparium</italic>&#x02019; and &#x02018;antimicrobial&#x02019; or &#x02018;antibacterial&#x02019; or &#x02018;anti-inflammatory&#x02019; or &#x02018;antiviral&#x02019; were tailored for individual databases to perform the search (a full search strategy is summarized in <xref ref-type="app" rid="app1-pharmaceuticals-13-00343">Appendix A</xref>). The retrieved articles were filtered manually to exclude duplicates and then screened using titles, abstracts and full-text articles based on our objectives. Also, bibliographies of included studies were reviewed to check for articles missed during the main search. Chemical structures and IUPAC names were obtained from PubChem. Information was also gathered from grey literature databases, Google search, targeted websites and Google Patents.</p><sec id="sec2dot1-pharmaceuticals-13-00343"><title>2.1. Chemical Composition</title><p>M&#x00101;nuka oil (CAS 219828- 87-2) is a volatile essential oil derived from the foliage, bark and seeds of <italic>Leptospermum scoparium</italic> plants of the <italic>Myrtaceae</italic> family of trees and shrubs [<xref rid="B4-pharmaceuticals-13-00343" ref-type="bibr">4</xref>]. A clear liquid with an aromatic odor is produced by a steam distillation process from plants harvested mostly in the autumn, summer and spring, with a yield ranging from 0.2&#x02013;1%, depending on seasonal and geographical factors [<xref rid="B5-pharmaceuticals-13-00343" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-13-00343" ref-type="bibr">6</xref>] (also commercial data held by Phytomed Medicinal Herbs Ltd., Auckland, New Zealand). The oil is generally distilled using leaves and young stems, although oil has also been produced from the seeds [<xref rid="B5-pharmaceuticals-13-00343" ref-type="bibr">5</xref>,<xref rid="B7-pharmaceuticals-13-00343" ref-type="bibr">7</xref>]. The use of biowaste fertilizer has recently been reported to enhance oil production and content [<xref rid="B8-pharmaceuticals-13-00343" ref-type="bibr">8</xref>].</p><p>A large number of studies have examined the constituents of m&#x00101;nuka oil, which vary depending on the source of the oil [<xref rid="B7-pharmaceuticals-13-00343" ref-type="bibr">7</xref>,<xref rid="B9-pharmaceuticals-13-00343" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-13-00343" ref-type="bibr">10</xref>] as well as the plant chemotype and season of collection [<xref rid="B11-pharmaceuticals-13-00343" ref-type="bibr">11</xref>]. Overall, 100 components were identified from 16 commercial samples of m&#x00101;nuka oil, of which 51 components made up 95% of the content [<xref rid="B7-pharmaceuticals-13-00343" ref-type="bibr">7</xref>]. The major components of commercially available m&#x00101;nuka oils are reported to be leptospermone (0.8&#x02013;19.4%), calamenene (2.5&#x02013;18.5%), &#x003b4;-cadinene (0.9&#x02013;6.9%), cadina-1,4-diene (0.1&#x02013;5.9%), flavesone (0.7&#x02013;5.8%), cadina-3,5-diene (3.0&#x02013;10.0%), &#x003b1;-copaene (4.3&#x02013;6.5%) and &#x003b1;-selinene (1.3&#x02013;5.0%) (<xref rid="pharmaceuticals-13-00343-t001" ref-type="table">Table 1</xref>) [<xref rid="B7-pharmaceuticals-13-00343" ref-type="bibr">7</xref>,<xref rid="B9-pharmaceuticals-13-00343" ref-type="bibr">9</xref>,<xref rid="B11-pharmaceuticals-13-00343" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-13-00343" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceuticals-13-00343" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceuticals-13-00343" ref-type="bibr">14</xref>]. Chemotypes found in the East Coast of the North Island of New Zealand tend to contain higher levels of &#x003b2;-triketones than oil sourced from other regions [<xref rid="B11-pharmaceuticals-13-00343" ref-type="bibr">11</xref>]. The compartmentalization of &#x003b2;-triketones and grandiflorone within oil glands inside m&#x00101;nuka leaves may defend the plants against m&#x00101;nuka&#x02019;s herbicidal activity [<xref rid="B15-pharmaceuticals-13-00343" ref-type="bibr">15</xref>]. There are also some types of <italic>L. scoparium</italic> that are high in &#x003b1;-pinene (21.5%) [<xref rid="B11-pharmaceuticals-13-00343" ref-type="bibr">11</xref>], though the majority of plants possess lower levels of this monoterpene (0.6&#x02013;11%) [<xref rid="B7-pharmaceuticals-13-00343" ref-type="bibr">7</xref>,<xref rid="B9-pharmaceuticals-13-00343" ref-type="bibr">9</xref>,<xref rid="B10-pharmaceuticals-13-00343" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-13-00343" ref-type="bibr">11</xref>].</p><p>Variation of the components in m&#x00101;nuka oil was found both between and within natural populations of <italic>L. scoparium</italic> [<xref rid="B7-pharmaceuticals-13-00343" ref-type="bibr">7</xref>,<xref rid="B11-pharmaceuticals-13-00343" ref-type="bibr">11</xref>,<xref rid="B16-pharmaceuticals-13-00343" ref-type="bibr">16</xref>]. Higher levels of triketones (known to have strong antibacterial properties) were predominant in samples from the East Cape population. Higher levels of the monoterpenes, &#x003b1;- and &#x003b2;-pinene, were present in the Northland populations [<xref rid="B16-pharmaceuticals-13-00343" ref-type="bibr">16</xref>]. Samples from <italic>L. scoparium</italic> grown in Australia had higher monoterpene levels and almost no triketones compared to those from New Zealand [<xref rid="B16-pharmaceuticals-13-00343" ref-type="bibr">16</xref>]. M&#x00101;nuka oil from New Zealand was shown to have low concentrations of monoterpenes in comparison to kanuka oil (75% &#x003b1;-pinene) and negligible amounts of terpinen-4-ol and 1,8-cineole predominant in Australian tea tree oil [<xref rid="B7-pharmaceuticals-13-00343" ref-type="bibr">7</xref>]. In general, m&#x00101;nuka oils from different geographic locations around New Zealand can be simplified into 3 basic chemo-type groups based on the ratio of the monoterpenes:sesquiterpenes:&#x000df;-triketones [<xref rid="B29-pharmaceuticals-13-00343" ref-type="bibr">29</xref>]. These include triketone-rich in the East Cape (marketed as Manex&#x02122;), monoterpene-, linalool- and eudesmol-rch in Nelson (Kaiteriteri&#x02122;) and monoterpene- and pinene rich in Canterbury [<xref rid="B5-pharmaceuticals-13-00343" ref-type="bibr">5</xref>,<xref rid="B9-pharmaceuticals-13-00343" ref-type="bibr">9</xref>,<xref rid="B16-pharmaceuticals-13-00343" ref-type="bibr">16</xref>,<xref rid="B30-pharmaceuticals-13-00343" ref-type="bibr">30</xref>]. A varied chemotype in m&#x00101;nuka grown in South Africa in comparison to New Zealand-grown was shown by van Vurren [<xref rid="B31-pharmaceuticals-13-00343" ref-type="bibr">31</xref>]. The age of the plant also plays a role in the nature of the essential oil, with higher sesquiterpene content in young plants and a mixed amount of monoterpenes and sesquiterpenes in mature ones [<xref rid="B9-pharmaceuticals-13-00343" ref-type="bibr">9</xref>]. </p><p>The lack of consistency in constituents is a common problem with natural extracts and a source of inconsistency in medicinal properties [<xref rid="B32-pharmaceuticals-13-00343" ref-type="bibr">32</xref>]. Though m&#x00101;nuka oil is listed under the New Zealand Inventory of chemicals (CAS 219828- 87-2), ECHA (CAS 223749-44-8) and EINECS (425-630-7), further research into regulation, standardization and characterization of the medicinal properties from varying origins is required.</p></sec><sec id="sec2dot2-pharmaceuticals-13-00343"><title>2.2. Medicinal Properties of M&#x00101;nuka Oil</title><p>M&#x00101;nuka grows abundantly throughout New Zealand and has been a part of traditional Maori medicine for a variety of applications. The bark of the tree has been used for the treatment of skin diseases, as a sedative and as a mouthwash. The leaves are boiled in water for treating colds or crushed and applied to ease itching and scabs, while the leaves have been used as tea, as a febrifuge and for pain relief. The seeds were used for treating dysentery and diarrhea [<xref rid="B33-pharmaceuticals-13-00343" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-13-00343" ref-type="bibr">34</xref>]. Contemporary data, prominently from in vitro studies, clearly demonstrates a broad spectrum of antibacterial, antifungal, anti-parasitic/insecticidal, anti-inflammatory, antiviral and spasmolytic activity.</p></sec><sec id="sec2dot3-pharmaceuticals-13-00343"><title>2.3. Antibacterial Activity</title><p>The antibacterial activity of m&#x00101;nuka oil is the most characterized, being effective against both Gram-positive and Gram-negative bacteria (<xref rid="pharmaceuticals-13-00343-t002" ref-type="table">Table 2</xref>). These effects are variable depending on the type and source of the oil, with fractions containing triketone constituents seeming particularly active [<xref rid="B10-pharmaceuticals-13-00343" ref-type="bibr">10</xref>].</p></sec><sec id="sec2dot4-pharmaceuticals-13-00343"><title>2.4. Mechanism of Action</title><p>The antibacterial activity of m&#x00101;nuka oil is relatively more pronounced against Gram positive bacteria than Gram negative bacteria (<xref rid="pharmaceuticals-13-00343-t002" ref-type="table">Table 2</xref>). The exact mechanism of the antibacterial effects in Gram positive bacteria are unknown but cell lysis of Gram-positive cells suggests disruption of the bacterial cell membrane is an important component of the mechanism. Treatment with 1.5% (<italic>v/v</italic>) of m&#x00101;nuka oil for 4 h induced morphological changes and cell lysis in methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA), while treatment with a high dose (3% <italic>v/v</italic>) completely disrupted the cells [<xref rid="B35-pharmaceuticals-13-00343" ref-type="bibr">35</xref>]. The &#x003b2;-triketone content are suggested to be responsible for this activity [<xref rid="B30-pharmaceuticals-13-00343" ref-type="bibr">30</xref>]. In contrast treatment with m&#x00101;nuka oil against Gram negative bacteria, such as <italic>E. coli</italic>, caused mild alterations in morphology at low doses and higher concentrations (6% <italic>v/v</italic>) were required for antibacterial effects [<xref rid="B12-pharmaceuticals-13-00343" ref-type="bibr">12</xref>,<xref rid="B35-pharmaceuticals-13-00343" ref-type="bibr">35</xref>]. The basis of the difference is unknown but this may be due to limited diffusion across the lipopolysaccharide-based capsule covering the outer membrane of Gram negative bacteria [<xref rid="B35-pharmaceuticals-13-00343" ref-type="bibr">35</xref>]. </p></sec><sec id="sec2dot5-pharmaceuticals-13-00343"><title>2.5. Gram Positive Bacteria</title><p>The efficacy of m&#x00101;nuka oil is both dose- and time-dependent. Treatment with a 10% solution of m&#x00101;nuka oil in DMSO was equally effective as the same concentration of kanuka oil against <italic>Staphylococcus aureus, Staphylococcus sobrinus and Staphylococcus mutans</italic> (Minimum Inhibitory Concentration (MIC) = 0.048% (480 &#x000b5;g/mL); the highest dilution at which no growth was observed) [<xref rid="B36-pharmaceuticals-13-00343" ref-type="bibr">36</xref>] (<xref rid="pharmaceuticals-13-00343-t002" ref-type="table">Table 2</xref>). A time to kill assay against the same strains showed 100% inhibition on treatment with either 10% m&#x00101;nuka oil or kanuka oil required as low as 5 s and as high as 900 s [<xref rid="B37-pharmaceuticals-13-00343" ref-type="bibr">37</xref>]. Another study determined the MIC value ranging between 0.13&#x02013;0.25% against <italic>S. sobrinus</italic> strains and 0.25% against <italic>S. mutans</italic> [<xref rid="B38-pharmaceuticals-13-00343" ref-type="bibr">38</xref>]. Higher concentrations of essential oils are reported in the case of other antibacterial medicinal products against the same oral pathogens&#x02014;tea tree (1%), eucalyptus (1%), lavender (&#x0003e;1%) and rosemary (&#x0003e;1%) [<xref rid="B38-pharmaceuticals-13-00343" ref-type="bibr">38</xref>] (<xref rid="pharmaceuticals-13-00343-t002" ref-type="table">Table 2</xref>). </p><p>M&#x00101;nuka oil exhibits strong bacteriostatic effects against different strains of <italic>Staphylococcus</italic>, including antibiotic-resistant strains (<xref rid="pharmaceuticals-13-00343-t002" ref-type="table">Table 2</xref>). Treatment with 2% (<italic>v/v</italic>) m&#x00101;nuka oil, kanuka oil or triketones in Tween 80 had limited bactericidal effects at 240 min post-treatment (using death a kinetics assay) [<xref rid="B30-pharmaceuticals-13-00343" ref-type="bibr">30</xref>]. M&#x00101;nuka oil has also exhibited strong activity against different strains of <italic>Staphylococcus pseudintermedius,</italic> often contributory to skin and ear infections in dogs [<xref rid="B39-pharmaceuticals-13-00343" ref-type="bibr">39</xref>]. These included methicillin-resistant strains, with MICs being around 2% (<italic>v/v</italic>) for both resistant- and antibiotic-sensitive isolates [<xref rid="B39-pharmaceuticals-13-00343" ref-type="bibr">39</xref>]. Inhibition of <italic>S. pseudintermedius</italic> biofilm formation was also reported in the same study [<xref rid="B39-pharmaceuticals-13-00343" ref-type="bibr">39</xref>]. Exposure of various strains of <italic>S. aureus</italic> to subinhibitory concentrations of m&#x00101;nuka oil has also been found to significantly inhibit their ability to produce enterotoxins, an effect not observed after treatment with oregano and marjoram essential oils [<xref rid="B36-pharmaceuticals-13-00343" ref-type="bibr">36</xref>,<xref rid="B40-pharmaceuticals-13-00343" ref-type="bibr">40</xref>]. </p><p>Activity against <italic>Staphylococcus epidermidis</italic> and <italic>Propionibacterium acnes</italic>, pathogenic bacteria responsible for acne in humans, has also been reported [<xref rid="B41-pharmaceuticals-13-00343" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceuticals-13-00343" ref-type="bibr">42</xref>]. Interestingly, this study also found m&#x00101;nuka oil to show the highest likelihood amongst a range of different essential oil combinations, of being involved in synergist interactions against <italic>S. epidermidis</italic> [<xref rid="B41-pharmaceuticals-13-00343" ref-type="bibr">41</xref>]. Kim et al. and Wu (2011) have shown reduction in acne and bactericidal effects (MIC = 0.211% <italic>w/v</italic> or 2.11 mg/mL; MBC = 0.25% <italic>w/v</italic> or 2.5 mg/mL) of m&#x00101;nuka oil against <italic>P. acnes</italic> respectively [<xref rid="B42-pharmaceuticals-13-00343" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-13-00343" ref-type="bibr">43</xref>].</p><p>Impressive effects of m&#x00101;nuka oil have been found against pathogenic bacteria associated with biosolid soil contamination, with significant growth inhibition of <italic>C. perfringens</italic> and <italic>L. monocytogenes</italic> [<xref rid="B44-pharmaceuticals-13-00343" ref-type="bibr">44</xref>]. The EC<sub>50</sub> = 0.07% and 23.3% (environmental effect concentration is the dose required to reduce pathogen growth by 50%) for <italic>C. perfringens</italic> and <italic>L. monocytogenes,</italic> respectively, on treatment with concentrated m&#x00101;nuka leaf extract for 24 h [<xref rid="B44-pharmaceuticals-13-00343" ref-type="bibr">44</xref>].</p><p>Specific components or fractions of m&#x00101;nuka oil, such as leptospermone (and its derivatives, grandiflorone and myrigalone A), have also been identified to possess antibacterial activity [<xref rid="B19-pharmaceuticals-13-00343" ref-type="bibr">19</xref>,<xref rid="B45-pharmaceuticals-13-00343" ref-type="bibr">45</xref>]. Leptospermone had the strongest inhibitory effect against foodborne Gram positive bacteria, such as <italic>Listeria monocytogenes, S. aureus and S. intermedius</italic> (<xref rid="pharmaceuticals-13-00343-t002" ref-type="table">Table 2</xref>), using both dilution assay and agar diffusion assay (&#x02265;30 mm inhibition zone on treatment with 1 and 2 mg/disc) [<xref rid="B19-pharmaceuticals-13-00343" ref-type="bibr">19</xref>]. Leptospermone and its derivative 1,2,3-cyclohexanetrione-1,3-dioxime had strong inhibitory effects against intestinal bacteria, <italic>Clostridium difficle</italic> and <italic>C. perfringens</italic> (inhibitory zone ranged between 20 and &#x0003e;30 mm on treatment with 2 or 5 mg/disc) [<xref rid="B19-pharmaceuticals-13-00343" ref-type="bibr">19</xref>]. The derivative 1,2,3-cyclohexanetrione-1,3-dioxime had a strong inhibitory effect against <italic>Bifidobacterium breve</italic> and <italic>B. longum</italic> (&#x02265;30 mm inhibition zone on treatment with 5 mg/disc) but leptospermum had no effect on these strains. Neither fractions were effective against <italic>Lactobacillus casei</italic>, a non-pathogenic probiotic [<xref rid="B19-pharmaceuticals-13-00343" ref-type="bibr">19</xref>]. </p><p>Two other components of typical m&#x00101;nuka oil, grandiflorone (MIC = up to 0.0032% or 32 &#x003bc;g/mL) and myrigalone A (MIC = 0.0064% or 64 &#x003bc;g/mL), have also been identified as active against vancomycin-resistant <italic>Enterococcus faecalis</italic> (VRE) and methicillin-resistant <italic>S. aureus</italic> (MRSA) and may therefore provide potential treatments for infection with these bacterial species [<xref rid="B45-pharmaceuticals-13-00343" ref-type="bibr">45</xref>]. </p></sec><sec id="sec2dot6-pharmaceuticals-13-00343"><title>2.6. Gram Negative Bacteria</title><p>A comprehensive study of the effects of 60 different essential oils on the growth of <italic>Helicobacter pylori</italic> (<italic>H. pylori</italic>) found m&#x00101;nuka oil to be the seventh most effective antibacterial when diluted in propylene glycol (500 &#x000b5;g/mL after 1 h and 40 &#x000b5;g/mL after 24 h) [<xref rid="B46-pharmaceuticals-13-00343" ref-type="bibr">46</xref>]. M&#x00101;nuka oil derived from the North Island of New Zealand displayed significant antibacterial activity against 20/20 <italic>Listeria monocytogenes</italic> strains, whereas more so than that of m&#x00101;nuka oil from the South Island was effective against (0/20 <italic>Listeria monocytogenes</italic> strains) [<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>]. Higher levels of &#x003b2;-triketones found in chemotypes growing in the North Island of New Zealand, are likely to be contributory to these differences [<xref rid="B11-pharmaceuticals-13-00343" ref-type="bibr">11</xref>]. </p><p>Investigation of the growth inhibitory effect of an oil from m&#x00101;nuka seeds against <italic>Escherichia coli</italic> showed it to be ineffective according to Jeong et al. (2009) while it was effective for Prosser et al. (2014). Based on calorimetric growth experiments using <italic>E. coli</italic> K12 C600, Jeong et al. (2009) showed that treatment with different doses of m&#x00101;nuka oil dissolved in Tween 80 (up to 4% <italic>v/v</italic>) had a dose-dependent effect in reducing bacterial growth but was not as effective as treatment with <italic>Melaleuca alternifolia</italic> oil [<xref rid="B47-pharmaceuticals-13-00343" ref-type="bibr">47</xref>]. On the other hand, Prosser et al. (2014) showed treatment with a very high dose of concentrated m&#x00101;nuka oil inhibited the growth of <italic>E. coli</italic> 0157 (EC<sub>50</sub> = 27.8%). Similar doses were required to inhibit the growth of <italic>Salmonella typhimurium</italic>. In comparison, treatment with 0.597% of concentrated m&#x00101;nuka oil was sufficient to retard the growth of <italic>C. jejuni</italic> [<xref rid="B44-pharmaceuticals-13-00343" ref-type="bibr">44</xref>]. This study proposed the potential applications to improve polluted soils and adjacent waterways, through planting m&#x00101;nuka or including m&#x00101;nuka oil when biosolids are applied to the soil to help prevent bacterial contamination [<xref rid="B44-pharmaceuticals-13-00343" ref-type="bibr">44</xref>,<xref rid="B48-pharmaceuticals-13-00343" ref-type="bibr">48</xref>].</p><p>M&#x00101;nuka-derived leptospermone has strong antibacterial activity against Gram negative foodborne bacterial pathogens, <italic>Salmonella typhimurium</italic>, <italic>Shigella flexneri</italic> and <italic>Shigella sonnei</italic>, with MICs ranging from 23.6 to 69.7 &#x003bc;g/mL [<xref rid="B49-pharmaceuticals-13-00343" ref-type="bibr">49</xref>]. These data suggest that leptospermone may be useful clinically or as a natural food preservative, as it is able to inhibit the growth of harmful gut and foodborne bacteria while displaying no significant effect on beneficial bacterial species [<xref rid="B49-pharmaceuticals-13-00343" ref-type="bibr">49</xref>]. </p><p>Activity against various Gram negative, antibiotic-resistant bacterial isolates from dogs with otitis externa, has also been reported recently for m&#x00101;nuka. These included both antibiotic-sensitive and multidrug-resistant clinical isolates of <italic>Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae spp. pneumoniae</italic> and <italic>Proteus mirabilis</italic> [<xref rid="B50-pharmaceuticals-13-00343" ref-type="bibr">50</xref>]. MIC and MBC values (minimum bactericidal concentrations) of m&#x00101;nuka oil alone were &#x02265;1% <italic>v/v</italic> and &#x02265;2%, respectively [<xref rid="B50-pharmaceuticals-13-00343" ref-type="bibr">50</xref>].</p><p>M&#x00101;nuka oil was the most effective against periodontopathic bacteria in comparison to tea tree oil, eucalyptus oil, lavandula oil and romarinus oil. M&#x00101;nuka oil was effective at very low concentration (MIC = 0.03%) against the oral pathogens <italic>A. actinomycetemcomitans</italic> (MBC = 0.13%)<italic>, P. gingivalis</italic> (MBC = 0.06; 0.03 for ATCC 53977) and <italic>F. nucleatum</italic> (MBC = 0.03%). By comparison, higher MIC values very observed for other antibacterial essential oils such as tea tree (0.06&#x02013;0.5%), eucalyptus (0.13&#x02013;0.5%), lavender (0.25&#x02013;1.0%) and rosemary (0.5&#x02013;1.0%) against the same oral pathogens [<xref rid="B38-pharmaceuticals-13-00343" ref-type="bibr">38</xref>]. </p></sec><sec id="sec2dot7-pharmaceuticals-13-00343"><title>2.7. Synergistic Effects</title><p>Combining m&#x00101;nuka oil with Tris-EDTA enhanced the antibacterial effects against drug-resistant isolates from dogs with otitis externa, with MIC value ranging from 0.06% to 0.5% and MBC value ranging from 0.06 to 1% [<xref rid="B50-pharmaceuticals-13-00343" ref-type="bibr">50</xref>]. A placebo-controlled study of bacterial pyoderma in dogs examined the effects of combining systemic antibiotics with a topical spray composed of essential oils, including m&#x00101;nuka oil [<xref rid="B51-pharmaceuticals-13-00343" ref-type="bibr">51</xref>]. The results showed a significant improvement in skin healing with the combination of oral antibiotics and essential oil spray, compared to oral antibiotics alone [<xref rid="B51-pharmaceuticals-13-00343" ref-type="bibr">51</xref>]. </p><p>Similar results highlighting the synergistic effects of m&#x00101;nuka oil were shown by Filoche (2005). The combined effect of chlorhexidine digluconate and a series of essential oils, including m&#x00101;nuka oil, found that m&#x00101;nuka oil inhibited the growth of two cariogenic bacteria, <italic>S. mutans</italic> and <italic>Lactobacillus plantarum,</italic> either as liquid cultures or as biofilms [<xref rid="B52-pharmaceuticals-13-00343" ref-type="bibr">52</xref>]. When m&#x00101;nuka oil and chlorhexidine were combined, the authors found an eight-fold reduction in the concentration of chlorhexidine required to achieve the same level of growth inhibition, suggesting the potential for novel anti-caries treatments [<xref rid="B52-pharmaceuticals-13-00343" ref-type="bibr">52</xref>]. </p><p>Combined treatment with <italic>Cananga odorata</italic> and m&#x00101;nuka oil had MIC = 0.094% (0.94 mg/mL) and 0.060% (0.60 mg/mL) against acne-causing <italic>Propionibacterium acnes</italic> (ATCC 11827) and <italic>Staphylococcus epidermidis</italic> (ATCC 2223), respectively. In comparison, treatment with each oil individually required higher doses (<xref rid="pharmaceuticals-13-00343-t002" ref-type="table">Table 2</xref>) (Orchard, 2018). Combined treatment with m&#x00101;nuka oil and <italic>Achillea millefolium</italic> or <italic>Citrus aurantium</italic> var. <italic>amara</italic> flower (neroli) had MIC = 1.0 mg/mL and 2.0 mg/mL against <italic>P. acnes</italic> and <italic>S. epidermidis,</italic> respectively, in the same study [<xref rid="B41-pharmaceuticals-13-00343" ref-type="bibr">41</xref>].</p></sec><sec id="sec2dot8-pharmaceuticals-13-00343"><title>2.8. Antifungal Activity</title><p>A summary of the antifungal effects of m&#x00101;nuka oil is given in <xref rid="pharmaceuticals-13-00343-t003" ref-type="table">Table 3</xref>. Although the exact mechanism of action is unknown, the essential oil from Melaleuca alternifolia (tea tree) has been shown to cause damage to the fungal cell wall and cytoplasmic membrane thereby altering the membranes properties and disrupting their functions. Melaleuca oil also causes thinning and distortion of the hyphal wall, causing cell wall disruption and formation of empty hyphal tips that create bud-like structures [<xref rid="B54-pharmaceuticals-13-00343" ref-type="bibr">54</xref>].</p><p>Moderate rate of inhibition of phytopathogenic fungi Phytophthora cactorum (28 &#x000d7; 103 mg/mL air), Cryphonectria parasitica (14 &#x000d7; 103 mg/mL air) and Fusarium circinatum (7 &#x000d7; 103 mg/mL air) was revealed fumigant assay [<xref rid="B55-pharmaceuticals-13-00343" ref-type="bibr">55</xref>]. When the fungi were exposed to m&#x00101;nuka oil as a fumigant, the inhibition rate was 50% against <italic>P. cactorum</italic> and 62% against F. circinatum; however, no inhibition was observed against C. parasitica [<xref rid="B55-pharmaceuticals-13-00343" ref-type="bibr">55</xref>]. </p><p>The effect of m&#x00101;nuka oil on Aspergillus niger, A. ochraceous and F. culmorum was assessed in another study, which found wide variation in the antifungal activity depending on the source of m&#x00101;nuka oil; the m&#x00101;nuka oil sample from the South Island of New Zealand had greater antifungal activity against A. ochraceus and F. culmorum than m&#x00101;nuka oil from the North Island [<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>]. The fungicidal activity of m&#x00101;nuka oil was assessed for a series of human fungal species, Malassezia furfur, Trichosporon mucoides, Candida albicans and C. tropicalis, with a MIC of 1.56% for M. furfur and T. mucoides and 3.13% for both Candida species [<xref rid="B37-pharmaceuticals-13-00343" ref-type="bibr">37</xref>]. Good activity against Candida species was also reported in a subsequent study [<xref rid="B56-pharmaceuticals-13-00343" ref-type="bibr">56</xref>].</p></sec><sec id="sec2dot9-pharmaceuticals-13-00343"><title>2.9. Antiparasitic/Insecticidal Activity</title><p>Several studies have examined the antiparasitic activity of m&#x00101;nuka oil, for parasites with significant impact on plants, humans and animals (<xref rid="pharmaceuticals-13-00343-t004" ref-type="table">Table 4</xref>). The primary animal parasites under investigation have been poultry red mites (<italic>Dermanyssus gallinae</italic>), while the primary human parasites investigated have been scabies (<italic>Sarcoptes scabei</italic>), house dust mites (<italic>Dermatophagoides farina</italic> and <italic>D. pteronyssinus</italic>), stored product mites (<italic>Tyrophagus putrescentiae</italic>) and mosquitos (<italic>Aedes aegypti</italic>). The adsorption of the active ingredients in the oil are suggested to cause fumigant and/or contact toxicity in the parasites. Contact and fumigation assays are generally used to determine the antiparasitic efficacy of essential oils. The compound efficacy would therefore depend on their lipophilic nature, viscosity and vapor pressure. In contact bioassays, lipophilic and viscous compounds are commonly more effective as they penetrate the cuticle layer of the arthropod. In fumigation bioassays, the toxic compounds are inhaled via the respiratory system and are dependent on the vapor pressure exerted by the compound [<xref rid="B57-pharmaceuticals-13-00343" ref-type="bibr">57</xref>].</p><p>A study of the effect of m&#x00101;nuka oil on different life stages of <italic>D. gallinae</italic> suggests it is effective against both adult and juvenile mites but that it is not ovicidal for this parasite [<xref rid="B58-pharmaceuticals-13-00343" ref-type="bibr">58</xref>]. A study of the effect of m&#x00101;nuka oil on <italic>D. gallinae</italic> found the lethal concentration required to kill 50% of the parasites (LC<sub>50</sub>) during a 24-h period in a contact bioassay was ~0.05 mg/cm<sup>3</sup> and 0.03 mg/cm<sup>3</sup> [<xref rid="B58-pharmaceuticals-13-00343" ref-type="bibr">58</xref>]. M&#x00101;nuka oil displayed a repelling effect on &#x0003e;75% of <italic>D. gallinae</italic> mites for up to 4 days after treatment of the mites contained in the Y-tube of an olfactometer and exposed to either fresh air in one arm of the Y-tube or air containing the volatile components of each essential oil in the other arm [<xref rid="B59-pharmaceuticals-13-00343" ref-type="bibr">59</xref>,<xref rid="B62-pharmaceuticals-13-00343" ref-type="bibr">62</xref>]. </p><p>The effect of m&#x00101;nuka oil on a poultry beetle (<italic>Tenebrio molitor),</italic> a beneficial insect in a poultry system, was assessed along with a non-target organism. In this case, the m&#x00101;nuka oil had no significant effect on beetle mortality compared to the control (~15% vs. ~5%, respectively) [<xref rid="B62-pharmaceuticals-13-00343" ref-type="bibr">62</xref>]. Similar results for <italic>T. molitor</italic> exposure to m&#x00101;nuka oil were observed in another study [<xref rid="B59-pharmaceuticals-13-00343" ref-type="bibr">59</xref>]. In contrast, exposure of brine shrimp (<italic>Artemia salina</italic>, an organism commonly used in toxicity testing) to m&#x00101;nuka oil revealed a 90% mortality rate after exposure to ~0.05 mg/cm<sup>3</sup>, the same concentration as the LC<sub>50</sub> for <italic>D. gallinae</italic> [<xref rid="B59-pharmaceuticals-13-00343" ref-type="bibr">59</xref>], indicating potential use of m&#x00101;nuka oil as a general acaricide may need careful consideration regarding the effect on non-target organisms. </p><p>M&#x00101;nuka seed oil appears to be effective against house dust (<italic>D. farina</italic> and <italic>D. pteronyssinus</italic>) and stored product mites (<italic>Tyrophagus putrescentiae</italic>), with a LD<sub>50</sub> (dose required to kill half the members of a tested population after a specified test duration) values of 0.54, 0.67 and 1.21 &#x000b5;g/cm<sup>2</sup>, respectively, against the stated parasites; these values are 11.5&#x02013;68.7 times more effective than DEET (<italic>N,N</italic>-diethyl-3-methylbenzamide), a common chemical treatment to control these mites [<xref rid="B20-pharmaceuticals-13-00343" ref-type="bibr">20</xref>]. Further analysis of the major components of m&#x00101;nuka seed oil indicated the main triketone, leptospermone, to be the most active component of m&#x00101;nuka oil in this study, with LD<sub>50</sub> values of 0.07&#x02013;0.15 ug/cm<sup>2</sup> against <italic>D. farina, D. pteronyssinus</italic> and <italic>T. putrescentiae</italic>; these values represent 92.6&#x02013;530.3 times the toxicity of DEET against the same organisms [<xref rid="B20-pharmaceuticals-13-00343" ref-type="bibr">20</xref>]. </p><p>A study of the effects of essential oils on human scabies mites (<italic>Sarcoptes scabei</italic>) found m&#x00101;nuka oil to be moderately effective against the mites, with median lethal times of 30 min (&#x000b1; 7.5 min) after direct contact with a 10% manuka oil solution in paraffin oil. Vapor phase toxicity of m&#x00101;nuka oil was determined via fumigation assay, where mites were exposed to a filter paper treated with m&#x00101;nuka oil and mortality was checked every 5 min. Median lethal time for undiluted m&#x00101;nuka oil was 23 min (&#x000b1; 8.7 min) [<xref rid="B14-pharmaceuticals-13-00343" ref-type="bibr">14</xref>]. </p><p>Insecticidal activity for m&#x00101;nuka oil has also been reported against <italic>Drosophila suzukii</italic>, a fruit fly pest which is a serious economic threat to soft summer fruit. M&#x00101;nuka oil&#x02019;s LD<sub>50</sub> for contact toxicity was 0.60 &#x003bc;g/mL for males and 1.10 for females. Triketone components were shown to be contributory to these insecticidal effects [<xref rid="B60-pharmaceuticals-13-00343" ref-type="bibr">60</xref>]. </p><p>M&#x00101;nuka oil has also been used as a lure to attract <italic>Xyleborus glabratus</italic> (Redbay ambrosia beetle), an exotic wood-borer that transmits the fungal agent (<italic>Raffaelea lauricola</italic>) responsible for laurel wilt, which has had a severe impact on forest ecosystems in South-East United States [<xref rid="B63-pharmaceuticals-13-00343" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceuticals-13-00343" ref-type="bibr">64</xref>].</p><p>Screening of essential oils for their toxicity against <italic>Aedes aegypti</italic> (L.) larvae found that m&#x00101;nuka oil containing calamenene and leptospermone as dominant constituents, exhibited strong larvicidal effects. This suggests potential applications for m&#x00101;nuka oil in mosquito vector control. These effects were enhanced when m&#x00101;nuka oil was combined with carvacrol or oregano oil [<xref rid="B61-pharmaceuticals-13-00343" ref-type="bibr">61</xref>] and with an emulsion made using amylose-N-1-hexadecylammonium chloride [<xref rid="B21-pharmaceuticals-13-00343" ref-type="bibr">21</xref>]. </p></sec><sec id="sec2dot10-pharmaceuticals-13-00343"><title>2.10. Anti-Inflammatory Effects</title><p>Experiments to assess the anti-inflammatory potential of m&#x00101;nuka oil found that THP-1 cells stimulated with lipopolysaccharide (LPS) and co-treated with 0.1&#x02013;10% m&#x00101;nuka oil had significantly reduced release of TNF-&#x003b1; but there was no significant effect on the release of IL-4 [<xref rid="B37-pharmaceuticals-13-00343" ref-type="bibr">37</xref>]. This study found no cellular toxicity at an oil concentration of 10%, which contrasts with the results discussed in the toxicity section earlier. The diluent used in the study by Chen et al. was not specified and this discrepancy could be a result of diluting the lipophilic m&#x00101;nuka oil in aqueous cell culture media. Lis-Balchin et al. (2000) also showed the antioxidant effects of m&#x00101;nuka oil from the North- and South-islands of New Zealand were more consistent in comparison to kanuka oil [<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>]. </p></sec><sec id="sec2dot11-pharmaceuticals-13-00343"><title>2.11. Photo-Protective Effects</title><p>Solar ultraviolet (UV) radiation is the primary environmental factor causing skin damage and consequently premature aging. Kwon et al. (2013) evaluated m&#x00101;nuka oil (from Coast Biologicals Ltd., Auckland, New Zealand) for its effects against photoaging in UV-B-irradiated hairless mice. After 8 weeks of exposure to UVB radiation, mice that were treated topically with 10% m&#x00101;nuka oil experienced a reduction in typical UVB-related skin changes, such as skin thickening, appearance of wrinkles and loss of skin collagen [<xref rid="B65-pharmaceuticals-13-00343" ref-type="bibr">65</xref>]. These effects were associated with inhibition of loss of collagen fibers, reduction of epidermal hyperplasia, suppressed production of proinflammatory cytokines (IL-1&#x003b2; and TNF-&#x003b1;) and reduced macrophage infiltration, suggesting m&#x00101;nuka oil can inhibit UVB-associated inflammation in skin [<xref rid="B65-pharmaceuticals-13-00343" ref-type="bibr">65</xref>]. </p><p>A nanoemulsion (particle size of 11.93 &#x000b5;m) containing m&#x00101;nuka oil (10% by weight) as the main component along with a Vitamin C derivative (ascorbyl tetraisopalmitate; 2% to 10% by weight) has been used in cosmetic formulations, including skin creams, lotions, essences and cosmetic powders [<xref rid="B66-pharmaceuticals-13-00343" ref-type="bibr">66</xref>]. The versatile formulation is effective as a whitening, anti-inflammatory agent and for wrinkle improvement [<xref rid="B66-pharmaceuticals-13-00343" ref-type="bibr">66</xref>]. Treatment for 9 weeks with the m&#x00101;nuka oil-Vitamin C derivative nanoemulsion in SKH-1 Hairless Mice exposed to artificial photoaging using UV-B irradiation showed increased thickness of the skin within 6 to 8 weeks post-treatment while the control showed no change.</p></sec><sec id="sec2dot12-pharmaceuticals-13-00343"><title>2.12. Antiviral Activity</title><p>Herpes simplex viruses can cause cold sores (usually Herpes simplex virus type 1, HSV-1) or genital herpes (usually Herpes simplex virus type 2, HSV-2) and both can become chronic and recurrent infections sometimes resistant to antiviral drugs [<xref rid="B67-pharmaceuticals-13-00343" ref-type="bibr">67</xref>]. Pre-treatment with a &#x003b2;-triketone-rich m&#x00101;nuka oil has been reported to exhibit inhibitory effects on HSV-1 and HSV-2 [<xref rid="B23-pharmaceuticals-13-00343" ref-type="bibr">23</xref>,<xref rid="B68-pharmaceuticals-13-00343" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceuticals-13-00343" ref-type="bibr">69</xref>]. RC-37 cells (monkey kidney cells) or the viruses were pre-treated with m&#x00101;nuka oil for one hour followed by inoculation. Pre-treatment of the virus with the oil significantly inhibited plaque formation in comparison to pre-treatment of the cells alone [<xref rid="B23-pharmaceuticals-13-00343" ref-type="bibr">23</xref>]. The IC<sub>50</sub> against HSV-1 was 0.96 &#x000b5;g/mL (0.0001% <italic>v/v</italic>) and that for HSV-2 was 0.587 &#x003bc;g/mL (0.00006% <italic>v/v</italic>) [<xref rid="B23-pharmaceuticals-13-00343" ref-type="bibr">23</xref>]. Pre-treatment of host cells before viral infection reduced replication of HSV-1 by 41%. Treatment with flavesone and leptospermone alone, two characteristic triketone constituents of m&#x00101;nuka oil, had similar effects [<xref rid="B23-pharmaceuticals-13-00343" ref-type="bibr">23</xref>]. Another study reported pre-treatment of acyclovir-resistant isolates of HSV-1 and HSV-2 with 0.001% m&#x00101;nuka oil reduced the infectivity of the viruses by &#x0003e;99% [<xref rid="B69-pharmaceuticals-13-00343" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceuticals-13-00343" ref-type="bibr">70</xref>]. The absence of viral inhibition in pre-treated cells suggests that the oil is likely to exert a direct antiviral effect on HSV before or during adsorption onto the host cells [<xref rid="B23-pharmaceuticals-13-00343" ref-type="bibr">23</xref>,<xref rid="B69-pharmaceuticals-13-00343" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceuticals-13-00343" ref-type="bibr">70</xref>].</p></sec><sec id="sec2dot13-pharmaceuticals-13-00343"><title>2.13. Spasmolytic Activity</title><p>Smooth muscle spasmolytic activity has been reported for m&#x00101;nuka oil in experiments on guinea pig ileum showing a dose-dependent inhibitory effect of m&#x00101;nuka oil on smooth muscle contractions [<xref rid="B71-pharmaceuticals-13-00343" ref-type="bibr">71</xref>]. A subsequent study of the components of m&#x00101;nuka oil showed &#x003b1;-terpineol and terpinene-4-ol both produce strong spasmolytic activity in guinea pig ileum, while in contrast, &#x003b1;- and &#x003b3;-terpinenes displayed spasmolytic activity after an initial spasmogenic action [<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>]. A post-synaptic mechanism affecting cAMP to alter potassium channels in the muscle was suggested by the authors as the possible mode of action [<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>]. This activity was absent in kanuka oil and neither m&#x00101;nuka or kanuka oil used cGMP nor behave like potassium channel openers (seen in <italic>Melaleuca</italic> (tea tree) oil). </p><p>M&#x00101;nuka oil and its components were also reported to increase muscle tone in skeletal muscle, evaluating its absorption in chick biventer muscle and rat phrenic nerve diaphragm preparations [<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>]. In contrast, both m&#x00101;nuka oil and <italic>Melaleuca</italic> oil decreased uterine muscle contractions. Application of either oils showed a decrease in tension (via inhibition of twitch response on stimulating the skeletal muscle nerve) and a weighty increase in resting tone (indicating contracture) when the muscle was stimulated either directly or via the phrenic nerve. the components &#x003b1;-terpineol, &#x003b1;-terpinene and terpinene-4-ol showing a similar, significant decrease in the force of contractions [<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>]. The study suggests the use of these oils for aromatherapy, where they would aid as relaxants for those suffering from stress and anxiety. While these studies involved relatively high doses of a limited number of m&#x00101;nuka oil samples, whose origins and chemotypes were not well characterized, to isolated tissues in vitro [<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>]. The researchers highlighted caution against the use of m&#x00101;nuka oil as a relaxant during childbirth may be detrimental to the birthing process and should therefore be avoided in this situation [<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>]. This suggestion was based on similar properties exhibited by tea tree oil and other essential oils [<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>,<xref rid="B72-pharmaceuticals-13-00343" ref-type="bibr">72</xref>].</p></sec><sec id="sec2dot14-pharmaceuticals-13-00343"><title>2.14. Safety and Tolerance</title><p>M&#x00101;nuka oil, like other essential oils, has been classified as safe and tolerable for human use (CAS (US and EU) 223749-44-8; CTFA monograph ID 10572 and EINECS 425-630-7). However, the lack of clinical trials means there is limited data to inform dosing practices and toxicology profiles. The in vitro toxicity of m&#x00101;nuka oil and its main constituent, leptospermone, tended to vary with cell lines, concentrations tested and method of analysis (<xref rid="pharmaceuticals-13-00343-t005" ref-type="table">Table 5</xref>). Higher cytotoxicity was observed on treatment with m&#x00101;nuka oil in comparison to leptospermone alone. This suggests additional components of m&#x00101;nuka oil that makes it more toxic to cell lines. A study of m&#x00101;nuka oil in human umbilical vein endothelial cells (HUVEC) found treatment with a concentration of 0.2% of m&#x00101;nuka oil reduced cell viability by ~30% [<xref rid="B38-pharmaceuticals-13-00343" ref-type="bibr">38</xref>]. Given m&#x00101;nuka oil is lipophilic and cannot be diluted in aqueous cell culture media [<xref rid="B69-pharmaceuticals-13-00343" ref-type="bibr">69</xref>], it is possible the actual concentration of m&#x00101;nuka oil in contact with the HUVEC cultures was significantly less than assumed.</p><p>No signs of toxicity were observed on treatment with 10% active aqueous or oily phase of the cosmetic formulation for Campo M&#x00101;nuka Oil Extract in fibroblast cells. In vitro organogenesis assay (Living Dermal Matrix (LDM)), a toxicity assay that closely mimics the effect of a substance on human skin, consists of skin cells in a 3D-construct made of collagen. The LDM test proved Campo M&#x00101;nuka oil to be non-irritant with 99.4% cell viability after treatment with an undiluted sample in comparison to 100% propylene glycol (73%; a non-irritant) and 100% morpholine (6%; a moderate irritant) [<xref rid="B73-pharmaceuticals-13-00343" ref-type="bibr">73</xref>]. </p><p>Unpublished data showed gel formulations containing &#x0003e;10% m&#x00101;nuka oil did not induce acute skin sensitivity in mice (unpublished data Phytomed Medicinal Herbs Ltd.). Acute toxicity was not observed (LD<sub>50</sub> = 4612 g/kg) in mice after single oral administration of varying doses (500 mg/kg to 5000 mg/kg) of a patented formulation containing a mix of <italic>Leptospermum scoparium</italic> and <italic>Kunzea ericoides</italic> essential oils. The same formulation did not induce erythema or edema 3 and 7 days after a skin irritation test in epilated rabbits treated with 0.5 g of the product. Absence of percutaneous irritation was also demonstrated after treatment with 0.1 mL of 10% emulsion of the combined oil product onto the eyes of rabbits treated up to 7 days [<xref rid="B74-pharmaceuticals-13-00343" ref-type="bibr">74</xref>].</p><p>Product safety report on MELORA&#x02122; M&#x00101;nuka oil (&#x0003c;5%) according to EC Regulation 1223/2009 detailed high skin tolerance and good cosmetic acceptability of the product. The formulation has a relatively high content of &#x003b2;-triketones, such as flavesone, isoleptospermone, leptospermone and grandiflorone. Acute toxicities based on the routes of administration were LD<sub>50</sub> = 1061 mg/kg body weight and LD<sub>50</sub> &#x0003e; 2000 mg/kg body weight for oral and dermal administration, respectively. No irritation was noted on testing the formulation on rabbit eye mucous membranes. There was no skin sensitization or genetic toxicity after a micronucleus test in TK6 Human lymphoblastoid cells and bacterial reverse mutation test in <italic>Salmonella typhimurium</italic> and <italic>E. coli</italic>. It is intended for external use, could cause irritations in the eye on direct contact and a patch test is suggested before use [<xref rid="B6-pharmaceuticals-13-00343" ref-type="bibr">6</xref>]. </p><p>The safety evaluations for Campo&#x02122; M&#x00101;nuka Oil Extract (10% concentrate in water or ceramide) formulation according to EC regulations described that the oil was non-toxic for dermal use and was edible in small quantities (oral LD<sub>50</sub> = &#x0003e;9000 mg/kg body weight) after testing in rats. The formulation was classified as a non-irritant based on tests in vivo and in healthy human subjects. Patch tests in 50 healthy human subjects at doses from 0.5% to 100% showed satisfactory tolerance with no significant irritation reactions [<xref rid="B73-pharmaceuticals-13-00343" ref-type="bibr">73</xref>]. The irritation potential of a 10% solution of m&#x00101;nuka oil was tested on the chorio-allantoic membrane of chicken egg, using the Eyetex assay and Skintex assay. All three tests deemed the formulation as non-irritant. The product did not have any comedogenic effect on the skin, indicating that the product does not clog pores and is well tolerated on the skin [<xref rid="B73-pharmaceuticals-13-00343" ref-type="bibr">73</xref>]. </p><p>Manuka oil sample pre-registered by the ECHA (EC Number: 434-370-3) was found to have LD<sub>50</sub>: 1.061 mg/kg body weight (95% CI: 722&#x02013;1.557) for oral administration and LD50 &#x0003e;2000 mg/kg body weight. Low scores for erythema and edema were determined for skin irritation and eye irritation tests in vivo. </p><p>M&#x00101;nuka oil is an active ingredient in the TGA-listed product Kiwiherb Herbal Throat Spray (ARTG ID 337576), which contains a mixture of <italic>Echinacea purpurea</italic> (6%), honey (7%), m&#x00101;nuka oil (1 &#x000b5;L/mL), <italic>Macropiper excelsum</italic> var. <italic>excelsum</italic> (7%), propolis tincture (0.09 &#x000b5;g/mL and <italic>Thymus vulgaris</italic> (5%). The formulation is accepted in Australia by TGA for oral administration to reduce or relieve cold, cough, dry throat, mild throat inflammation, itchy throat and pharyngitis [<xref rid="B75-pharmaceuticals-13-00343" ref-type="bibr">75</xref>]. </p></sec></sec><sec id="sec3-pharmaceuticals-13-00343"><title>3. Future Directions</title><p>M&#x00101;nuka oil has been extensively used in traditional medicinal preparations and its individual fractions, particularly <italic>&#x003b2;</italic>-triketone constituents, exhibit many bioactive properties. Yet its application in clinical medicine remains under explored. The emergence of new strains of pathogens, including bacteria, viruses, parasites and fungi, coupled with the continued rise in antibiotic resistance, warrants further study of the potential antimicrobial activity of essential oils as therapeutic agents for their control and eradication. In contrast to tea tree oil, there is limited evidence on the efficacy and safety of m&#x00101;nuka oil in terms of geographic origin, parts of the plant used, dilutions and variation among formulations. The elucidated mechanisms of action exerted by topical application of m&#x00101;nuka oil are general to those of essential oils. Further reproducible studies looking into the mechanistic and lethal action of m&#x00101;nuka oil as well as its fractions are required to accurately compare efficacy between formulations and sources of the oil. Future studies on the synergistic efficacy of m&#x00101;nuka oil with synthetic drugs or other essential oils could improve its efficacy against pathogen, for instance Gram negative bacteria. In vivo studies on the medicinal properties of m&#x00101;nuka oil could inform therapeutic and interventional clinical trials. Additionally, there is a clear need for standardization of manuka oil (e.g., the International Organization for Standardization [ISO] and Association Fran&#x000e7;aise de Normalization [AFNOR] for quality specification of key bioactive terpene components) to meet the growing needs of therapeutic grade product.</p></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-13-00343"><title>4. Conclusions</title><p>With emerging resistance to drug-based antimicrobial and anti-parasitic treatments, as well as a growing interest in alternative therapies, the extensive in vitro data supporting the medicinal properties of m&#x00101;nuka oil warrant further clinical studies to characterize its true therapeutic benefits. Commercialization and therapeutic application of m&#x00101;nuka oil requires extensive regulation and standardization of the oil and clinical evidence for its medicinal properties. The review highlights an underutilized essential oil with potential medical applications similar to tea tree oil and m&#x00101;nuka honey. Further characterization of antimicrobial activity of manuka oil will clearly improve its potential to become a clinically useful product. The current in vitro data suggest that manuka oil products may have efficacy in the treatment of many cutaneous skin infections. These data also provide a sound basis from which to proceed to in vivo and clinical work&#x02014;which is critical in translating early laboratory findings into clinically useful outcomes.</p><p>Since the mechanism of action has implications for the selectivity and safety of antimicrobial agents, this issue is becoming increasingly important. Despite growing interest in the oil for therapeutic purposes, the current data remains limited, highlighting the need for further research to understand how manuka oil works. There is enormous potential to expand the manuka oil industry if claims about its medicinal properties are to be verified. Scientific validation regarding the antimicrobial activity of manuka oil may assist in accessing of international markets and the registration of the oil with national regulatory bodies. </p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by Faculty of Health, University of Canberra and Phytomed Medicinal Herbs Ltd., New Zealand.</p></ack><fn-group><fn><p><bold>Publisher&#x02019;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>C.M.: Writing-Original draft and table preparation. W.T., G.M.P., A.B., and M.S.: Reviewing and Editing. P.R.: Reviewing and Editing. J.T.: Conceptualization, editing, reviewing and Supervision. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>The review did not receive any external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Authors declare no conflict of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECHA</td><td align="left" valign="middle" rowspan="1" colspan="1">European Chemicals Agency</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MIC</td><td align="left" valign="middle" rowspan="1" colspan="1">Minimum inhibitory concentrations</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MBC</td><td align="left" valign="middle" rowspan="1" colspan="1">Minimum Bactericidal Concentration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EINECS</td><td align="left" valign="middle" rowspan="1" colspan="1">European Inventory of Existing Commercial chemical Substances</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">% <italic>v/v</italic></td><td align="left" valign="middle" rowspan="1" colspan="1">volume per volume</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VRE</td><td align="left" valign="middle" rowspan="1" colspan="1">vancomycin-resistant <italic>Enterococcus faecalis</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MRSA</td><td align="left" valign="middle" rowspan="1" colspan="1">methicillin-resistant <italic>S. aureus</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATCC</td><td align="left" valign="middle" rowspan="1" colspan="1">American Type Culture Collection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EDTA</td><td align="left" valign="middle" rowspan="1" colspan="1">Ethylenediaminetetraacetic acid</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LC<sub>50</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">lethal concentration required to kill 50% of the parasites</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LD<sub>50</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">dose required to kill half the members of a tested population after a specified test duration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LPS</td><td align="left" valign="middle" rowspan="1" colspan="1">lipopolysaccharide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor necrosis factor alpha</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">UV</td><td align="left" valign="middle" rowspan="1" colspan="1">ultraviolet</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HSV</td><td align="left" valign="middle" rowspan="1" colspan="1">Herpes simplex virus</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IC<sub>50</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">half maximal inhibitory concentration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">US</td><td align="left" valign="middle" rowspan="1" colspan="1">United States of America</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EU</td><td align="left" valign="middle" rowspan="1" colspan="1">European Union</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CTFA</td><td align="left" valign="middle" rowspan="1" colspan="1">Cosmetic, Toiletry and Fragrance Association</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HUVEC</td><td align="left" valign="middle" rowspan="1" colspan="1">human umbilical vein endothelial cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LDM</td><td align="left" valign="middle" rowspan="1" colspan="1">Living Dermal Matrix</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">3D</td><td align="left" valign="middle" rowspan="1" colspan="1">three-dimensional</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ARTG</td><td align="left" valign="middle" rowspan="1" colspan="1">Australian Register of Therapeutic Goods.</td></tr></tbody></array></glossary><app-group><app id="app1-pharmaceuticals-13-00343"><title>Appendix A</title><table-wrap id="pharmaceuticals-13-00343-t0A1" orientation="portrait" position="anchor"><object-id pub-id-type="pii">pharmaceuticals-13-00343-t0A1_Table A1</object-id><label>Table A1</label><caption><p>Search Strategy for PubMed and Embase (Via Scopus).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PubMed</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Search Strategies </th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">#1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(&#x0201c;leptospermum&#x0201d;[MeSH Terms] OR &#x0201c;leptospermum&#x0201d;[All Fields]) OR &#x0201c;leptospermums scoparium&#x0201d;[All Fields]) OR (&#x0201c;manuka&#x0201d;[All Fields] AND &#x0201c;oil&#x0201d;[All Fields])) OR ((&#x0201c;tea tree oil&#x0201d;[MeSH Terms] OR &#x0201c;tea tree oil&#x0201d;[All Fields] NOT (honey) [All Fields])</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">#2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">((&#x0201c;antifungal&#x0201d;[All Fields]) OR ((((((&#x0201c;anti-infective agents&#x0201d; OR &#x0201c;anti-infective agents&#x0201d;[MeSH Terms]) OR &#x0201c;anti-infective agents&#x0201d;[All Fields]) OR &#x0201c;antimicrobial&#x0201d;[All Fields]) OR &#x0201c;anti-microbial&#x0201d;[All Fields]) OR &#x0201c;antimicrobials&#x0201d;[All Fields] OR anti-inflammatory OR anti-inflammatory OR antiviral OR anti-viral OR &#x0201c;anti-viral agents&#x0201d;))</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">#3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">#1 AND #2</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Embase (via Scopus)</bold>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">#1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">leptospermum OR &#x0201c;leptospermums scoparium&#x0201d; OR &#x0201c;manuka oil&#x0201d; OR &#x0201c;tea tree oil&#x0201d; OR &#x0201c;tea tree&#x0201d; NOT &#x0201c;honey&#x0201d;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">#2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0201c;anti-infective agents&#x0201d; OR antibacterial OR &#x0201c;antibacterial agent&#x0201d; OR &#x0201c;anti-infective agents&#x0201d; OR &#x0201c;anti-infective agents&#x0201d; OR &#x0201c;antimicrobial&#x0201d; OR &#x0201c;anti-microbial&#x0201d; OR &#x0201c;antimicrobials&#x0201d; OR anti-inflammatory OR anti-inflammatory OR antiviral OR anti-viral OR &#x0201c;anti-viral agents&#x0201d;</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">#3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">#1 AND #2 </td></tr></tbody></table></table-wrap></app></app-group><ref-list><title>References</title><ref id="B1-pharmaceuticals-13-00343"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>P.G.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>M.M.</given-names></name><name><surname>Gadek</surname><given-names>P.A.</given-names></name><name><surname>Quinn</surname><given-names>C.J.</given-names></name><name><surname>Quinn</surname><given-names>P.A.G.J.</given-names></name></person-group><article-title>Myrtaceae revisited: A reassessment of infrafamilial groups</article-title><source>Am. J. Bot.</source><year>2001</year><volume>88</volume><fpage>2013</fpage><lpage>2025</lpage><pub-id pub-id-type="doi">10.2307/3558428</pub-id><pub-id pub-id-type="pmid">21669634</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-13-00343"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maddocks-Jennings</surname><given-names>W.</given-names></name><name><surname>Wilkinson</surname><given-names>J.M.</given-names></name><name><surname>Cavanagh</surname><given-names>H.</given-names></name><name><surname>Shillington</surname><given-names>D.</given-names></name></person-group><article-title>Evaluating the effects of the essential oils Leptospermum scoparium (manuka) and Kunzea ericoides (kanuka) on radiotherapy induced mucositis: A randomized, placebo controlled feasibility study</article-title><source>Eur. J. Oncol. Nurs.</source><year>2009</year><volume>13</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.ejon.2009.01.002</pub-id><pub-id pub-id-type="pmid">19297246</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-13-00343"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>C.F.</given-names></name><name><surname>Riley</surname><given-names>T.V.</given-names></name></person-group><article-title>Safety, efficacy and provenance of tea tree (Melaleuca alternifolia) oil</article-title><source>Contact Dermat.</source><year>2001</year><volume>45</volume><fpage>65</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0536.2001.045002065.x</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-13-00343"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avonto</surname><given-names>C.</given-names></name><name><surname>Chittiboyina</surname><given-names>A.G.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Vasquez</surname><given-names>Y.</given-names></name><name><surname>Rua</surname><given-names>D.</given-names></name><name><surname>A Khan</surname><given-names>I.</given-names></name></person-group><article-title>In Chemico Evaluation of Tea Tree Essential Oils as Skin Sensitizers: Impact of the Chemical Composition on Aging and Generation of Reactive Species</article-title><source>Chem. Res. Toxicol.</source><year>2016</year><volume>29</volume><fpage>1108</fpage><lpage>1117</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrestox.5b00530</pub-id><?supplied-pmid 27286037?><pub-id pub-id-type="pmid">27286037</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-13-00343"><label>5.</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Broadsheet</surname><given-names>C.F.R.</given-names></name></person-group><article-title>Essential Oil Production from Manuka &#x00026; Kanuka</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://tararuacropping.files.wordpress.com/2016/08/essential-oil-manuka-may-2014_kanuka.pdf">https://tararuacropping.files.wordpress.com/2016/08/essential-oil-manuka-may-2014_kanuka.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-20">(accessed on 20 June 2020)</date-in-citation></element-citation></ref><ref id="B6-pharmaceuticals-13-00343"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Melora</collab></person-group><source>Cosmetic Product Safety Report: MELORA&#x02122; M&#x00101;nuka Oil</source><publisher-name>Melora</publisher-name><publisher-loc>Dublin, Ireland</publisher-loc><year>2017</year></element-citation></ref><ref id="B7-pharmaceuticals-13-00343"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christoph</surname><given-names>F.</given-names></name><name><surname>Kubeczka</surname><given-names>K.-H.</given-names></name><name><surname>Stahl-Biskup</surname><given-names>E.</given-names></name></person-group><article-title>The Composition of Commercial Manuka Oils from New Zealand</article-title><source>J. Essent. Oil Res.</source><year>1999</year><volume>11</volume><fpage>705</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1080/10412905.1999.9712001</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-13-00343"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seyedalikhani</surname><given-names>S.</given-names></name><name><surname>Esperschuetz</surname><given-names>J.</given-names></name><name><surname>Dickinson</surname><given-names>N.</given-names></name><name><surname>Hofmann</surname><given-names>R.</given-names></name><name><surname>Breitmeyer</surname><given-names>J.</given-names></name><name><surname>Horswell</surname><given-names>J.</given-names></name><name><surname>Robinson</surname><given-names>B.</given-names></name></person-group><article-title>Biowastes to augment the essential oil production of Leptospermum scoparium and Kunzea robusta in low-fertility soil</article-title><source>Plant Physiol. Biochem.</source><year>2019</year><volume>137</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.plaphy.2019.02.008</pub-id><?supplied-pmid 30802804?><pub-id pub-id-type="pmid">30802804</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-13-00343"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>N.G.</given-names></name><name><surname>Smale</surname><given-names>P.E.</given-names></name><name><surname>Nelson</surname><given-names>M.A.</given-names></name><name><surname>Hay</surname><given-names>A.J.</given-names></name><name><surname>Van Klink</surname><given-names>J.W.</given-names></name><name><surname>Dean</surname><given-names>C.M.</given-names></name></person-group><article-title>Variability in essential oil chemistry and plant morphology within aLeptospermum scopariumpopulation</article-title><source>N. Z. J. Bot.</source><year>1998</year><volume>36</volume><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1080/0028825X.1998.9512551</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-13-00343"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>N.G.</given-names></name><name><surname>Wilkins</surname><given-names>A.L.</given-names></name></person-group><article-title>Chemical, physical and antimicrobial properties of essential oils of Leptospermum scoparium and Kunzea ericoides</article-title><source>Phytochemistry</source><year>1999</year><volume>50</volume><fpage>407</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(98)00548-2</pub-id><pub-id pub-id-type="pmid">9933953</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-13-00343"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>M.H.</given-names></name><name><surname>Van Klink</surname><given-names>J.W.</given-names></name><name><surname>Smallfield</surname><given-names>B.M.</given-names></name><name><surname>Perry</surname><given-names>N.B.</given-names></name><name><surname>Anderson</surname><given-names>R.E.</given-names></name><name><surname>Johnstone</surname><given-names>P.</given-names></name><name><surname>Weavers</surname><given-names>R.T.</given-names></name></person-group><article-title>Essential oils from New Zealand manuka: Triketone and other chemotypes of Leptospermum scoparium</article-title><source>Phytochemistry</source><year>2004</year><volume>65</volume><fpage>1255</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1016/j.phytochem.2004.03.019</pub-id><?supplied-pmid 15184010?><pub-id pub-id-type="pmid">15184010</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-13-00343"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christoph</surname><given-names>F.</given-names></name><name><surname>Kaulfers</surname><given-names>P.M.</given-names></name><name><surname>Stahl-Biskup</surname><given-names>E.</given-names></name></person-group><article-title>In vitro evaluation of the antibacterial activity of &#x003b2;-triketones admixed to Melaleuca oils</article-title><source>Planta Med.</source><year>2001</year><volume>67</volume><fpage>768</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1055/s-2001-18350</pub-id><?supplied-pmid 11731927?><pub-id pub-id-type="pmid">11731927</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-13-00343"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christoph</surname><given-names>F.</given-names></name><name><surname>Stahl-Biskup</surname><given-names>E.</given-names></name><name><surname>Kaulfers</surname><given-names>P.M.</given-names></name></person-group><article-title>Death Kinetics of Staphylococcus aureus Exposed to Commercial Tea Tree Oils s.l</article-title><source>J. Essent. Oil Res.</source><year>2001</year><volume>13</volume><fpage>98</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1080/10412905.2001.9699625</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-13-00343"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>F.</given-names></name><name><surname>Candy</surname><given-names>K.</given-names></name><name><surname>Melloul</surname><given-names>E.</given-names></name><name><surname>Bernigaud</surname><given-names>C.</given-names></name><name><surname>Chai</surname><given-names>L.</given-names></name><name><surname>Darmon</surname><given-names>C.</given-names></name><name><surname>Durand</surname><given-names>R.</given-names></name><name><surname>Botterel</surname><given-names>F.</given-names></name><name><surname>Chosidow</surname><given-names>O.</given-names></name><name><surname>Izri</surname><given-names>A.</given-names></name><etal/></person-group><article-title>In vitro activity of ten essential oils against Sarcoptes scabiei</article-title><source>Parasites Vectors</source><year>2016</year><volume>9</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1186/s13071-016-1889-3</pub-id><?supplied-pmid 27876081?><pub-id pub-id-type="pmid">26728523</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-13-00343"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killeen</surname><given-names>D.P.</given-names></name><name><surname>Van Klink</surname><given-names>J.W.</given-names></name><name><surname>Smallfield</surname><given-names>B.M.</given-names></name><name><surname>Gordon</surname><given-names>K.C.</given-names></name><name><surname>Perry</surname><given-names>N.B.</given-names></name></person-group><article-title>Herbicidal &#x003b2;-triketones are compartmentalized in leaves of Leptospermumspecies: Localization by Raman microscopy and rapid screening</article-title><source>New Phytol.</source><year>2015</year><volume>205</volume><fpage>339</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1111/nph.12970</pub-id><?supplied-pmid 25103692?><pub-id pub-id-type="pmid">25103692</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-13-00343"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>N.B.</given-names></name><name><surname>Brennan</surname><given-names>N.J.</given-names></name><name><surname>Van Klink</surname><given-names>J.W.</given-names></name><name><surname>Harris</surname><given-names>W.</given-names></name><name><surname>Douglas</surname><given-names>M.H.</given-names></name><name><surname>McGimpsey</surname><given-names>J.A.</given-names></name><name><surname>Smallfield</surname><given-names>B.M.</given-names></name><name><surname>Anderson</surname><given-names>R.E.</given-names></name></person-group><article-title>Essential oils from New Zealand manuka and kanuka: Chemotaxonomy of Leptospermum</article-title><source>Phytochemistry</source><year>1997</year><volume>44</volume><fpage>1485</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(96)00743-1</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-13-00343"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>N.B.</given-names></name><name><surname>Van Klink</surname><given-names>J.W.</given-names></name><name><surname>Brennan</surname><given-names>N.J.</given-names></name><name><surname>Harris</surname><given-names>W.</given-names></name><name><surname>Anderson</surname><given-names>R.E.</given-names></name><name><surname>Douglas</surname><given-names>M.H.</given-names></name><name><surname>Smallfield</surname><given-names>B.M.</given-names></name></person-group><article-title>Essential oils from new zealand manuka and kanuka: Chemotaxonomy of kunzea</article-title><source>Phytochemistry</source><year>1997</year><volume>45</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(97)00203-3</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-13-00343"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dayan</surname><given-names>F.E.</given-names></name><name><surname>Howell</surname><given-names>J.L.</given-names></name><name><surname>Marais</surname><given-names>J.P.</given-names></name><name><surname>Ferreira</surname><given-names>D.</given-names></name><name><surname>Koivunen</surname><given-names>M.</given-names></name></person-group><article-title>Manuka Oil, A Natural Herbicide with Preemergence Activity</article-title><source>Weed Sci.</source><year>2011</year><volume>59</volume><fpage>464</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1614/WS-D-11-00043.1</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-13-00343"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>E.Y.</given-names></name><name><surname>Jeon</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>H.W.</given-names></name><name><surname>Kim</surname><given-names>M.G.</given-names></name><name><surname>Lee</surname><given-names>H.S.</given-names></name></person-group><article-title>Antimicrobial activity of leptospermone and its derivatives against human intestinal bacteria</article-title><source>Food Chem.</source><year>2009</year><volume>115</volume><fpage>1401</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1016/j.foodchem.2009.01.086</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-13-00343"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>E.Y.</given-names></name><name><surname>Kim</surname><given-names>M.G.</given-names></name><name><surname>Lee</surname><given-names>H.S.</given-names></name></person-group><article-title>Acaricidal activity of triketone analogues derived fromLeptospermum scopariumoil against house-dust and stored-food mites</article-title><source>Pest Manag. Sci.</source><year>2009</year><volume>65</volume><fpage>327</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1002/ps.1684</pub-id><pub-id pub-id-type="pmid">19051215</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-13-00343"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muturi</surname><given-names>E.J.</given-names></name><name><surname>Selling</surname><given-names>G.W.</given-names></name><name><surname>Doll</surname><given-names>K.M.</given-names></name><name><surname>Hay</surname><given-names>W.T.</given-names></name><name><surname>Ramirez</surname><given-names>J.L.</given-names></name></person-group><article-title>Leptospermum scoparium essential oil is a promising source of mosquito larvicide and its toxicity is enhanced by a biobased emulsifier</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e229076</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0229076</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-13-00343"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Govindarajan</surname><given-names>M.</given-names></name><name><surname>Rajeswary</surname><given-names>M.</given-names></name><name><surname>Benelli</surname><given-names>G.</given-names></name></person-group><article-title>&#x003b4;-Cadinene, Calarene and &#x003b4;-4-Carene from Kadsura heteroclita Essential Oil as Novel Larvicides Against Malaria, Dengue and Filariasis Mosquitoes</article-title><source>Comb. Chem. High Throughput Screen.</source><year>2016</year><volume>19</volume><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.2174/1386207319666160506123520</pub-id><pub-id pub-id-type="pmid">27151483</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-13-00343"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reichling</surname><given-names>J.</given-names></name><name><surname>Koch</surname><given-names>C.</given-names></name><name><surname>Stahl-Biskup</surname><given-names>E.</given-names></name><name><surname>Sojka</surname><given-names>C.</given-names></name><name><surname>Schnitzler</surname><given-names>P.</given-names></name></person-group><article-title>Virucidal Activity of a &#x003b2;-Triketone-Rich Essential Oil ofLeptospermum scoparium (Manuka Oil) Against HSV-1 and HSV-2 in Cell Culture</article-title><source>Planta Med.</source><year>2005</year><volume>71</volume><fpage>1123</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1055/s-2005-873175</pub-id><?supplied-pmid 16395648?><pub-id pub-id-type="pmid">16395648</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-13-00343"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelly</surname><given-names>T.E.</given-names></name><name><surname>Cowan</surname><given-names>A.N.</given-names></name><name><surname>Edu</surname><given-names>J.</given-names></name><name><surname>Pahio</surname><given-names>E.</given-names></name></person-group><article-title>Mating success of male Mediterranean fruit flies following exposure to two sources of alpha-copaene, manuka oil and mango</article-title><source>Fla. Entomol.</source><year>2008</year><volume>91</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1653/0015-4040(2008)091[0009:MSOMMF]2.0.CO;2</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-13-00343"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanula</surname><given-names>J.L.</given-names></name><name><surname>Mayfield</surname><given-names>A.E.</given-names><suffix>III</suffix></name><name><surname>Reid</surname><given-names>L.S.</given-names></name><name><surname>Horn</surname><given-names>S.</given-names></name></person-group><article-title>Influence of trap distance from a source population and multiple traps on captures and attack densities of the redbay ambrosia beetle (Coleoptera: Curculionidae: Scolytinae)</article-title><source>J. Econol. Entomol.</source><year>2016</year><volume>109</volume><fpage>1196</fpage><lpage>1204</lpage><pub-id pub-id-type="doi">10.1093/jee/tow068</pub-id><?supplied-pmid 27053703?><pub-id pub-id-type="pmid">27053703</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-13-00343"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>An</surname><given-names>P.</given-names></name><name><surname>Qi</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>X.</given-names></name></person-group><article-title>Antifungal mechanisms of &#x003b1;-terpineol and terpene-4-alcohol as the critical components of Melaleuca alternifolia oil in the inhibition of rot disease caused by Aspergillus ochraceus in postharvest grapes</article-title><source>J. Appl. Microbiol.</source><year>2019</year><volume>126</volume><fpage>1161</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1111/jam.14193</pub-id><?supplied-pmid 30614164?><pub-id pub-id-type="pmid">30614164</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-13-00343"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogueira</surname><given-names>M.N.M.</given-names></name><name><surname>Aquino</surname><given-names>S.G.</given-names></name><name><surname>Rossa Junior</surname><given-names>C.</given-names></name><name><surname>Spolidorio</surname><given-names>D.M.P.</given-names></name></person-group><article-title>Terpinen-4-ol and alpha-terpineol (tea tree oil components) inhibit the production of IL-1&#x003b2;, IL-6 and IL-10 on human macrophages</article-title><source>Inflamm. Res.</source><year>2014</year><volume>63</volume><fpage>769</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1007/s00011-014-0749-x</pub-id><?supplied-pmid 24947163?><pub-id pub-id-type="pmid">24947163</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-13-00343"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lis-Balchin</surname><given-names>M.</given-names></name><name><surname>Hart</surname><given-names>S.L.</given-names></name><name><surname>Deans</surname><given-names>S.G.</given-names></name></person-group><article-title>Pharmacological and antimicrobial studies on different tea-tree oils (Melaleuca alternifolia, Leptospermum scoparium or Manuka and Kunzea ericoides or Kanuka), originating in Australia and New Zealand</article-title><source>Phytotherapy Res.</source><year>2000</year><volume>14</volume><fpage>623</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1002/1099-1573(200012)14:8&#x0003c;623::AID-PTR763&#x0003e;3.0.CO;2-Z</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-13-00343"><label>29.</label><element-citation publication-type="web"><article-title>Manuka Oil Beta Troketones. Manuka Essential Oil</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://www.mbtk.org.nz/what-msstk/manuka-essential-oil/">http://www.mbtk.org.nz/what-msstk/manuka-essential-oil/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-23">(accessed on 23 June 2020)</date-in-citation></element-citation></ref><ref id="B30-pharmaceuticals-13-00343"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christoph</surname><given-names>F.</given-names></name><name><surname>Kaulfers</surname><given-names>P.-M.</given-names></name><name><surname>Stahl-Biskup</surname><given-names>E.</given-names></name></person-group><article-title>A Comparative Study of the in vitro Antimicrobial Activity of Tea Tree Oils s.l. with Special Reference to the Activity of &#x003b2;-Triketones</article-title><source>Planta Med.</source><year>2000</year><volume>66</volume><fpage>556</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1055/s-2000-8604</pub-id><pub-id pub-id-type="pmid">10985085</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-13-00343"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Vuuren</surname><given-names>S.</given-names></name><name><surname>Docrat</surname><given-names>Y.</given-names></name><name><surname>Kamatou</surname><given-names>G.</given-names></name><name><surname>Viljoen</surname><given-names>A.M.</given-names></name></person-group><article-title>Essential oil composition and antimicrobial interactions of understudied tea tree species</article-title><source>S. Afr. J. Bot.</source><year>2014</year><volume>92</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.sajb.2014.01.005</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-13-00343"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bent</surname><given-names>S.</given-names></name></person-group><article-title>Herbal Medicine in the United States: Review of Efficacy, Safety, and Regulation: Grand Rounds at University of California, San Francisco Medical Center</article-title><source>J. Gen. Intern. Med.</source><year>2008</year><volume>23</volume><fpage>854</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1007/s11606-008-0632-y</pub-id><pub-id pub-id-type="pmid">18415652</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-13-00343"><label>33.</label><element-citation publication-type="gov"><article-title>M&#x00101;ori Medicine</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.tepapa.govt.nz/discover-collections/read-watch-play/maori/maori-medicine">https://www.tepapa.govt.nz/discover-collections/read-watch-play/maori/maori-medicine</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-23">(accessed on 23 June 2020)</date-in-citation></element-citation></ref><ref id="B34-pharmaceuticals-13-00343"><label>34.</label><element-citation publication-type="web"><article-title>Plant Use Details: Leptospermum scoparium. M&#x00101;nuka. Kahikatoa</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://maoriplantuse.landcareresearch.co.nz/WebForms/PeoplePlantsDetails.aspx?PKey=34969a5f-698d-437d-8a84-c71dd21351a5">https://maoriplantuse.landcareresearch.co.nz/WebForms/PeoplePlantsDetails.aspx?PKey=34969a5f-698d-437d-8a84-c71dd21351a5</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-06-23">(accessed on 23 June 2020)</date-in-citation></element-citation></ref><ref id="B35-pharmaceuticals-13-00343"><label>35.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Alnaimat</surname><given-names>S.</given-names></name><name><surname>Wainwright</surname><given-names>M.</given-names></name><name><surname>Jaber</surname><given-names>S.</given-names></name><name><surname>Amasha</surname><given-names>R.</given-names></name></person-group><article-title>Mechanism of the Antibacterial Action of (Leptospermum scoparium) Oil on Methicillin-resistant Staphylococcus aureus (MRSA)and E. coli)</article-title><source>Proceedings of the 2nd Mediterranean Symposium on Medicinal and Aromatic Plants (MESMAP-2)</source><conf-loc>Antalya, Turkey</conf-loc><conf-date>22&#x02013;25 April 2015</conf-date></element-citation></ref><ref id="B36-pharmaceuticals-13-00343"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fratini</surname><given-names>F.</given-names></name><name><surname>Mancini</surname><given-names>S.</given-names></name><name><surname>Turchi</surname><given-names>B.</given-names></name><name><surname>Friscia</surname><given-names>E.</given-names></name><name><surname>Pistelli</surname><given-names>L.</given-names></name><name><surname>Giusti</surname><given-names>G.</given-names></name><name><surname>Cerri</surname><given-names>D.</given-names></name></person-group><article-title>A novel interpretation of the Fractional Inhibitory Concentration Index: The case Origanum vulgare L. and Leptospermum scoparium J.R. et G. Forst essential oils against Staphylococcus aureus strains</article-title><source>Microbiol. Res.</source><year>2017</year><volume>195</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2016.11.005</pub-id><?supplied-pmid 28024521?><pub-id pub-id-type="pmid">28024521</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-13-00343"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.C.</given-names></name><name><surname>Yan</surname><given-names>S.H.</given-names></name><name><surname>Yen</surname><given-names>M.Y.</given-names></name><name><surname>Wu</surname><given-names>P.F.</given-names></name><name><surname>Liao</surname><given-names>W.T.</given-names></name><name><surname>Huang</surname><given-names>T.S.</given-names></name><name><surname>Wen</surname><given-names>Z.H.</given-names></name><name><surname>Wang</surname><given-names>H.M.D.</given-names></name></person-group><article-title>Investigations of kanuka and manuka essential oils for in vitro treatment of disease and cellular inflammation caused by infectious microorganisms</article-title><source>J. Microbiol. Immunol. Infect.</source><year>2016</year><volume>49</volume><fpage>104</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2013.12.009</pub-id><pub-id pub-id-type="pmid">24582465</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-13-00343"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takarada</surname><given-names>K.</given-names></name><name><surname>Kimizuka</surname><given-names>R.</given-names></name><name><surname>Takahashi</surname><given-names>N.</given-names></name><name><surname>Honma</surname><given-names>K.</given-names></name><name><surname>Okuda</surname><given-names>K.</given-names></name><name><surname>Kato</surname><given-names>T.</given-names></name></person-group><article-title>A comparison of the antibacterial efficacies of essential oils against oral pathogens</article-title><source>Oral Microbiol. Immunol.</source><year>2004</year><volume>19</volume><fpage>61</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1046/j.0902-0055.2003.00111.x</pub-id><?supplied-pmid 14678476?><pub-id pub-id-type="pmid">14678476</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-13-00343"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>C.Y.</given-names></name><name><surname>Nam</surname><given-names>E.H.</given-names></name><name><surname>Park</surname><given-names>S.H.</given-names></name><name><surname>Hwang</surname><given-names>C.Y.</given-names></name></person-group><article-title>In vitroefficacy of the essential oil fromLeptospermum scoparium(manuka) on antimicrobial susceptibility and biofilm formation inStaphylococcus pseudintermediusisolates from dogs</article-title><source>Veter Dermatol.</source><year>2013</year><volume>24</volume><fpage>404</fpage><pub-id pub-id-type="doi">10.1111/vde.12045</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-13-00343"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turchi</surname><given-names>B.</given-names></name><name><surname>Mancini</surname><given-names>S.</given-names></name><name><surname>Pistelli</surname><given-names>L.</given-names></name><name><surname>Najar</surname><given-names>B.</given-names></name><name><surname>Fratini</surname><given-names>F.</given-names></name></person-group><article-title>Sub-inhibitory concentration of essential oils induces antibiotic resistance in Staphylococcus aureus</article-title><source>Nat. Prod. Res.</source><year>2019</year><volume>33</volume><fpage>1509</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1080/14786419.2017.1419237</pub-id><pub-id pub-id-type="pmid">29272983</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-13-00343"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orchard</surname><given-names>A.</given-names></name><name><surname>Van Vuuren</surname><given-names>S.</given-names></name><name><surname>Viljoen</surname><given-names>A.M.</given-names></name><name><surname>Kamatou</surname><given-names>G.P.P.</given-names></name></person-group><article-title>The in vitro antimicrobial evaluation of commercial essential oils and their combinations against acne</article-title><source>Int. J. Cosmet. Sci.</source><year>2018</year><volume>40</volume><fpage>226</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1111/ics.12456</pub-id><?supplied-pmid 29574906?><pub-id pub-id-type="pmid">29574906</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-13-00343"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Joo</surname><given-names>C.</given-names></name><name><surname>Choe</surname><given-names>T.</given-names></name></person-group><article-title>The effects of antimicrobial properties of manuka oil and improvement of acne</article-title><source>J. Korean Soc. Cosmetol.</source><year>2011</year><volume>17</volume><fpage>245</fpage><lpage>256</lpage></element-citation></ref><ref id="B43-pharmaceuticals-13-00343"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name></person-group><article-title>Antimicrobial Effect of Manuka Honey and Kanuka Honey Alone and in Combination with the Bioactives Against the Growth of Propionibacterium Acnes ATCC 6919</article-title><source>Master&#x02019;s Thesis</source><publisher-name>Massey University</publisher-name><publisher-loc>Auckland, New Zealand</publisher-loc><month>6</month><year>2011</year></element-citation></ref><ref id="B44-pharmaceuticals-13-00343"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prosser</surname><given-names>J.</given-names></name><name><surname>Anderson</surname><given-names>C.</given-names></name><name><surname>Horswell</surname><given-names>J.</given-names></name><name><surname>Speir</surname><given-names>T.</given-names></name></person-group><article-title>Can manuka (Leptospermum scoparium) antimicrobial properties be utilised in the remediation of pathogen contaminated land?</article-title><source>Soil Biol. Biochem.</source><year>2014</year><volume>75</volume><fpage>167</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.soilbio.2014.04.003</pub-id></element-citation></ref><ref id="B45-pharmaceuticals-13-00343"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killeen</surname><given-names>D.P.</given-names></name><name><surname>Larsen</surname><given-names>L.</given-names></name><name><surname>Dayan</surname><given-names>F.E.</given-names></name><name><surname>Gordon</surname><given-names>K.C.</given-names></name><name><surname>Perry</surname><given-names>N.B.</given-names></name><name><surname>Van Klink</surname><given-names>J.W.</given-names></name></person-group><article-title>Nortriketones: Antimicrobial Trimethylated Acylphloroglucinols from M&#x00101;nuka (Leptospermum scoparium)</article-title><source>J. Nat. Prod.</source><year>2016</year><volume>79</volume><fpage>564</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1021/acs.jnatprod.5b00968</pub-id><?supplied-pmid 26731565?><pub-id pub-id-type="pmid">26731565</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-13-00343"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergonzelli</surname><given-names>G.</given-names></name><name><surname>Donnicola</surname><given-names>D.</given-names></name><name><surname>Porta</surname><given-names>N.</given-names></name><name><surname>Corth&#x000e9;sy-TheulazI</surname><given-names>E.</given-names></name></person-group><article-title>Essential Oils as Components of a Diet-Based Approach to Management of Helicobacter Infection</article-title><source>Antimicrob. Agents Chemother.</source><year>2003</year><volume>47</volume><fpage>3240</fpage><lpage>3246</lpage><pub-id pub-id-type="doi">10.1128/AAC.47.10.3240-3246.2003</pub-id><?supplied-pmid 14506036?><pub-id pub-id-type="pmid">14506036</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-13-00343"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmolz</surname><given-names>E.</given-names></name><name><surname>Doebner</surname><given-names>R.</given-names></name><name><surname>Auste</surname><given-names>R.</given-names></name><name><surname>Daum</surname><given-names>R.</given-names></name><name><surname>Welge</surname><given-names>G.</given-names></name><name><surname>Lamprecht</surname><given-names>I.</given-names></name></person-group><article-title>Bioenergetic investigations on tea-tree and related essential oils</article-title><source>Thermochim. Acta</source><year>1999</year><volume>337</volume><fpage>71</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/S0040-6031(99)00231-2</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-13-00343"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prosser</surname><given-names>J.</given-names></name><name><surname>Woods</surname><given-names>R.</given-names></name><name><surname>Horswell</surname><given-names>J.</given-names></name><name><surname>Robinson</surname><given-names>B.</given-names></name></person-group><article-title>The potential in-situ antimicrobial ability of Myrtaceae plant species on pathogens in soil</article-title><source>Soil Biol. Biochem.</source><year>2016</year><volume>96</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.soilbio.2015.12.007</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-13-00343"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>E.Y.</given-names></name><name><surname>Lee</surname><given-names>M.J.</given-names></name><name><surname>Lee</surname><given-names>H.S.</given-names></name></person-group><article-title>Antimicrobial activities of leptospermone isolated from Leptospermum scoparium seeds and structure-activity relationships of its derivatives against foodborne bacteria</article-title><source>Food Sci. Biotechnol.</source><year>2018</year><volume>27</volume><fpage>1541</fpage><lpage>1547</lpage><pub-id pub-id-type="doi">10.1007/s10068-018-0391-4</pub-id><?supplied-pmid 30319866?><pub-id pub-id-type="pmid">30319866</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-13-00343"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>S.</given-names></name><name><surname>Hyun</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>J.H.</given-names></name><name><surname>Hwang</surname><given-names>C.Y.</given-names></name></person-group><article-title>In vitro antibacterial activity of the manuka essential oil from Leptospermum scoparium combined with Tris-EDTA against Gram-negative bacterial isolates from dogs with otitis externa</article-title><source>Veter Dermatol.</source><year>2020</year><volume>31</volume><fpage>81</fpage><pub-id pub-id-type="doi">10.1111/vde.12807</pub-id><?supplied-pmid 31729809?><pub-id pub-id-type="pmid">31729809</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-13-00343"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensignor</surname><given-names>E.</given-names></name><name><surname>Fabri&#x000e8;s</surname><given-names>L.</given-names></name><name><surname>Bailleux</surname><given-names>L.</given-names></name></person-group><article-title>A split-body, randomized, blinded study to evaluate the efficacy of a topical spray composed of essential oils and essential fatty acids from plant extracts with antimicrobial properties</article-title><source>Veter Dermatol.</source><year>2016</year><volume>27</volume><fpage>464</fpage><pub-id pub-id-type="doi">10.1111/vde.12374</pub-id><?supplied-pmid 27597636?><pub-id pub-id-type="pmid">27597636</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-13-00343"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filoche</surname><given-names>S.K.</given-names></name><name><surname>Soma</surname><given-names>K.</given-names></name><name><surname>Sissons</surname><given-names>C.H.</given-names></name></person-group><article-title>Antimicrobial effects of essential oils in combination with chlorhexidine digluconate</article-title><source>Oral Microbiol. Immunol.</source><year>2005</year><volume>20</volume><fpage>221</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1111/j.1399-302X.2005.00216.x</pub-id><pub-id pub-id-type="pmid">15943766</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-13-00343"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwiertz</surname><given-names>A.</given-names></name><name><surname>Duttke</surname><given-names>C.</given-names></name><name><surname>Hild</surname><given-names>J.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>H.J.</given-names></name></person-group><article-title>In vitro activity of essential oils on microorganisms isolated from vaginal infections</article-title><source>Int. J. Aromatherapy</source><year>2006</year><volume>16</volume><fpage>169</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.ijat.2006.09.005</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-13-00343"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hammer</surname><given-names>K.</given-names></name><name><surname>Carson</surname><given-names>C.F.</given-names></name><name><surname>Riley</surname><given-names>T.V.</given-names></name></person-group><article-title>Antifungal effects of Melaleuca alternifolia (tea tree) oil and its components on Candida albicans, Candida glabrata and Saccharomyces cerevisiae</article-title><source>J. Antimicrob. Chemother.</source><year>2004</year><volume>53</volume><fpage>1081</fpage><lpage>1085</lpage><pub-id pub-id-type="doi">10.1093/jac/dkh243</pub-id><pub-id pub-id-type="pmid">15140856</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-13-00343"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.S.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Lee</surname><given-names>S.G.</given-names></name><name><surname>Oh</surname><given-names>E.</given-names></name><name><surname>Shin</surname><given-names>S.C.</given-names></name><name><surname>Park</surname><given-names>I.K.</given-names></name></person-group><article-title>Effects of plant essential oils and components from Oriental sweetgum (Liquidambar orientalis) on growth and morphogenesis of three phytopathogenic fungi</article-title><source>Pestic. Biochem. Physiol.</source><year>2009</year><volume>93</volume><fpage>138</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1016/j.pestbp.2009.02.002</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-13-00343"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elisa</surname><given-names>B.</given-names></name><name><surname>Aldo</surname><given-names>A.</given-names></name><name><surname>Ludovica</surname><given-names>G.</given-names></name><name><surname>Viviana</surname><given-names>P.</given-names></name><name><surname>Debora</surname><given-names>B.</given-names></name><name><surname>Massa</surname><given-names>N.</given-names></name><name><surname>Giorgia</surname><given-names>N.</given-names></name><name><surname>Elisa</surname><given-names>G.</given-names></name></person-group><article-title>Chemical composition and antimycotic activity of six essential oils (cumin, fennel, manuka, sweet orange, cedar and juniper) against different Candida spp.</article-title><source>Nat. Prod. Res.</source><year>2019</year><volume>11</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.1080/14786419.2019.1696327</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-13-00343"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Audino</surname><given-names>P.</given-names></name><name><surname>Picollo</surname><given-names>M.I.</given-names></name><name><surname>Gallardo</surname><given-names>A.</given-names></name><name><surname>Toloza</surname><given-names>A.</given-names></name><name><surname>Vassena</surname><given-names>C.</given-names></name><name><surname>Cueto</surname><given-names>G.M.</given-names></name></person-group><article-title>Comparative toxicity of oxygenated monoterpenoids in experimental hydroalcoholic lotions to permethrin-resistant adult head lice</article-title><source>Arch. Dermatol. Res.</source><year>2010</year><volume>303</volume><fpage>361</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1007/s00403-010-1110-z</pub-id><pub-id pub-id-type="pmid">21174108</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-13-00343"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>D.R.</given-names></name><name><surname>Sparagano</surname><given-names>O.A.E.</given-names></name><name><surname>Port</surname><given-names>G.</given-names></name><name><surname>Okello</surname><given-names>E.</given-names></name><name><surname>Shiel</surname><given-names>R.S.</given-names></name><name><surname>Guy</surname><given-names>J.H.</given-names></name></person-group><article-title>Environmental interactions with the toxicity of plant essential oils to the poultry red miteDermanyssus gallinae</article-title><source>Med. Veter Entomol.</source><year>2010</year><volume>24</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2915.2009.00855.x</pub-id><?supplied-pmid 20377725?><pub-id pub-id-type="pmid">20377725</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-13-00343"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>D.R.</given-names></name><name><surname>Sparagano</surname><given-names>O.A.E.</given-names></name><name><surname>Port</surname><given-names>G.</given-names></name><name><surname>Okello</surname><given-names>E.</given-names></name><name><surname>Shiel</surname><given-names>R.S.</given-names></name><name><surname>Guy</surname><given-names>J.H.</given-names></name></person-group><article-title>Toxicity of plant essential oils to different life stages of the poultry red mite, Dermanyssus gallinae, and non-target invertebrates</article-title><source>Med. Veter Entomol.</source><year>2010</year><volume>24</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2915.2009.00856.x</pub-id><?supplied-pmid 20377726?><pub-id pub-id-type="pmid">20377726</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-13-00343"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>C.G.</given-names></name><name><surname>Jang</surname><given-names>M.</given-names></name><name><surname>Shin</surname><given-names>E.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name></person-group><article-title>Myrtaceae Plant Essential Oils and their &#x003b2;-Triketone Components as Insecticides against Drosophila suzukii</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>1050</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22071050</pub-id><?supplied-pmid 28672824?><pub-id pub-id-type="pmid">28672824</pub-id></element-citation></ref><ref id="B61-pharmaceuticals-13-00343"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muturi</surname><given-names>E.J.</given-names></name><name><surname>Ramirez</surname><given-names>J.L.</given-names></name><name><surname>Doll</surname><given-names>K.M.</given-names></name><name><surname>Bowman</surname><given-names>M.J.</given-names></name></person-group><article-title>Combined Toxicity of Three Essential Oils Against Aedes aegypti (Diptera: Culicidae) Larvae</article-title><source>J. Med. Entomol.</source><year>2017</year><volume>54</volume><fpage>1684</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1093/jme/tjx168</pub-id><?supplied-pmid 29029151?><pub-id pub-id-type="pmid">29029151</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-13-00343"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>D.R.</given-names></name><name><surname>Sparagano</surname><given-names>O.A.E.</given-names></name><name><surname>Port</surname><given-names>G.</given-names></name><name><surname>Okello</surname><given-names>E.</given-names></name><name><surname>Shiel</surname><given-names>R.</given-names></name><name><surname>Guy</surname><given-names>J.</given-names></name></person-group><article-title>Repellence of plant essential oils to Dermanyssus gallinae and toxicity to the non-target invertebrate Tenebrio molitor</article-title><source>Veter Parasitol.</source><year>2009</year><volume>162</volume><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2009.02.009</pub-id><?supplied-pmid 19264408?><pub-id pub-id-type="pmid">19264408</pub-id></element-citation></ref><ref id="B63-pharmaceuticals-13-00343"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kendra</surname><given-names>P.E.</given-names></name><name><surname>Montgomery</surname><given-names>W.S.</given-names></name><name><surname>Niogret</surname><given-names>J.</given-names></name><name><surname>Deyrup</surname><given-names>M.A.</given-names></name><name><surname>Guill&#x000e9;n</surname><given-names>L.</given-names></name><name><surname>Epsky</surname><given-names>N.D.</given-names></name></person-group><article-title>Xyleborus glabratus, X. affinis, and X. ferrugineus (Coleoptera: Curculionidae: Scolytinae): Electroantennogram Responses to Host-Based Attractants and Temporal Patterns in Host-Seeking Flight</article-title><source>Environ. Entomol.</source><year>2012</year><volume>41</volume><fpage>1597</fpage><lpage>1605</lpage><pub-id pub-id-type="doi">10.1603/EN12164</pub-id><pub-id pub-id-type="pmid">23321108</pub-id></element-citation></ref><ref id="B64-pharmaceuticals-13-00343"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanula</surname><given-names>J.L.</given-names></name><name><surname>Sullivan</surname><given-names>B.T.</given-names></name><name><surname>Wakarchuk</surname><given-names>D.</given-names></name></person-group><article-title>Variation in Manuka Oil Lure Efficacy for CapturingXyleborus glabratus (Coleoptera: Curculionidae: Scolytinae), and Cubeb Oil as an Alternative Attractant</article-title><source>Environ. Entomol.</source><year>2013</year><volume>42</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1603/EN12337</pub-id><?supplied-pmid 23575024?><pub-id pub-id-type="pmid">23575024</pub-id></element-citation></ref><ref id="B65-pharmaceuticals-13-00343"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>O.S.</given-names></name><name><surname>Jung</surname><given-names>S.H.</given-names></name><name><surname>Yang</surname><given-names>B.S.</given-names></name></person-group><article-title>Topical Administration of Manuka Oil Prevents UV-B Irradiation-Induced Cutaneous Photoaging in Mice</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2013</year><volume>2013</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1155/2013/930857</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-13-00343"><label>66.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Park</surname><given-names>M.-I.</given-names></name><name><surname>Lee</surname><given-names>B.-J.</given-names></name><name><surname>Lee</surname><given-names>S.W.</given-names></name><name><surname>Tag</surname><given-names>H.</given-names></name><name><surname>Soonkyu</surname><given-names>J.</given-names></name></person-group><article-title>Vitamin C Derivative and Manuka Oil Surface Treated Composite Powder for Skin-Whitening and Wrinkle-Care</article-title><patent>Patent KR101639615B1</patent><day>15</day><month>7</month><year>2016</year></element-citation></ref><ref id="B67-pharmaceuticals-13-00343"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Looker</surname><given-names>K.J.</given-names></name><name><surname>Garnett</surname><given-names>G.P.</given-names></name></person-group><article-title>A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2</article-title><source>Sex. Transm. Infect.</source><year>2005</year><volume>81</volume><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1136/sti.2004.012039</pub-id><?supplied-pmid 15800084?><pub-id pub-id-type="pmid">15800084</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-13-00343"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Astani</surname><given-names>A.</given-names></name><name><surname>Reichling</surname><given-names>J.</given-names></name><name><surname>Schnitzler</surname><given-names>P.</given-names></name></person-group><article-title>Screening for Antiviral Activities of Isolated Compounds from Essential Oils</article-title><source>Evid. Based Complement. Altern. Med.</source><year>2011</year><volume>2011</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1093/ecam/nep187</pub-id></element-citation></ref><ref id="B69-pharmaceuticals-13-00343"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnitzler</surname><given-names>P.</given-names></name><name><surname>Wiesenhofer</surname><given-names>K.</given-names></name><name><surname>Reichling</surname><given-names>J.</given-names></name></person-group><article-title>Comparative study on the cytotoxicity of different Myrtaceae essential oils on cultured vero and RC-37 cells</article-title><source>Die Pharm.</source><year>2008</year><volume>63</volume><fpage>830</fpage><lpage>835</lpage></element-citation></ref><ref id="B70-pharmaceuticals-13-00343"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnitzler</surname><given-names>P.</given-names></name></person-group><article-title>Essential Oils for the Treatment of Herpes Simplex Virus Infections</article-title><source>Chemotherapy</source><year>2019</year><volume>64</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1159/000501062</pub-id><?supplied-pmid 31234166?><pub-id pub-id-type="pmid">31234166</pub-id></element-citation></ref><ref id="B71-pharmaceuticals-13-00343"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lis-Balchin</surname><given-names>M.</given-names></name><name><surname>Hart</surname><given-names>S.L.</given-names></name></person-group><article-title>An Investigation of the Actions of the Essential oils of Manuka (Leptospermum scoparium) and Kanuka (Kunzea ericoides), Myrtaceae on Guinea-pig Smooth Muscle</article-title><source>J. Pharm. Pharmacol.</source><year>1998</year><volume>50</volume><fpage>809</fpage><lpage>811</lpage><pub-id pub-id-type="doi">10.1111/j.2042-7158.1998.tb07144.x</pub-id><pub-id pub-id-type="pmid">9720632</pub-id></element-citation></ref><ref id="B72-pharmaceuticals-13-00343"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lis-Balchin</surname><given-names>M.</given-names></name></person-group><article-title>Essential oils and &#x02019;aromatherapy&#x02019;: Their modern role in healing</article-title><source>J. R. Soc. Health</source><year>1997</year><volume>117</volume><fpage>324</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1177/146642409711700511</pub-id><?supplied-pmid 9519666?><pub-id pub-id-type="pmid">9519666</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-13-00343"><label>73.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Campo Research PTE Ltd.</collab></person-group><source>Manuka Oil Extract Leptospermum Scoparium</source><publisher-name>Campo Research PTE Ltd.</publisher-name><publisher-loc>Singapore</publisher-loc><year>2015</year></element-citation></ref><ref id="B74-pharmaceuticals-13-00343"><label>74.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>J.-G.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Hong</surname><given-names>N.</given-names></name></person-group><article-title>External Preparation for Antibacterial, Anti-Inflammatory and Skin Protection Containing Manuka Oil as a Main Ingredient</article-title><patent>Patent KR19990016741A</patent><day>12</day><month>5</month><year>2003</year></element-citation></ref><ref id="B75-pharmaceuticals-13-00343"><label>75.</label><element-citation publication-type="gov"><article-title>Searching the Australian Register of Therapeutic Goods (ARTG)</article-title><comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.tga.gov.au/searching-australian-register-therapeutic-goods-artg">https://www.tga.gov.au/searching-australian-register-therapeutic-goods-artg</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2020-07-01">(accessed on 1 July 2020)</date-in-citation></element-citation></ref></ref-list></back><floats-group><table-wrap id="pharmaceuticals-13-00343-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-13-00343-t001_Table 1</object-id><label>Table 1</label><caption><p>Chemical composition of M&#x00101;nuka oil and known properties of each component.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Component</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Percentage in Commercial Compositions</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IUPAC Name</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Known Properties</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;-pinene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Up to 21.5%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-13-00343-i001.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported to have antibiotic resistance modulation, anticoagulant, antitumor, antimicrobial, antimalarial, antioxidant, anti-inflammatory, anti-Leishmania, and analgesic effects in association with other essential oils.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B16-pharmaceuticals-13-00343" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-13-00343" ref-type="bibr">17</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Leptospermone </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8&#x02013;19.4%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6-isovaleryl-2,2,4,4-tetramethyl-1,3,5-cyclohexanetrione<break/>
<inline-graphic xlink:href="pharmaceuticals-13-00343-i002.jpg"/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Herbicidal; antibacterial: treatment with 5&#x02013;20 mg/disc of concentrate was effective against foodborne bacteria: <italic>Listeria monocytogenes, Staphylococcus aureus and Staphylococcus intermedius</italic> and three Gram-negative bacteria: <italic>Salmonella typhimurium, Shigella flexneri and Shigella sonnei</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B18-pharmaceuticals-13-00343" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceuticals-13-00343" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-13-00343" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Calamenene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5&#x02013;18.5%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,6-Dimethyl-4-isopropyltetralin<break/>
<inline-graphic xlink:href="pharmaceuticals-13-00343-i003.jpg"/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Major constituent of m&#x00101;nuka oil; contributes to insecticidal, antiseptic, bactericidal, analgesic and anti-inflammatory properties.<break/> Antibacterial effect against <italic>S. aureus</italic> and MRSA was shown.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B12-pharmaceuticals-13-00343" ref-type="bibr">12</xref>,<xref rid="B21-pharmaceuticals-13-00343" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b4;-cadinene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.9&#x02013;6.9%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-13-00343-i004.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pesticidal effects against mosquito have been shown for constituents isolated from <italic>Kadsura heteroclita</italic> leaf oil.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B22-pharmaceuticals-13-00343" ref-type="bibr">22</xref>] </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cadina-1,4-diene </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1&#x02013;5.9%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-13-00343-i005.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cadina-3,5-diene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.0&#x02013;10.0%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-13-00343-i006.jpg"/>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Flavesone </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7&#x02013;5.8%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2,2,4,4-Tetramethyl-6-(3-methylbutanoyl)cyclohexane-1,3,5-trione<break/>
<inline-graphic xlink:href="pharmaceuticals-13-00343-i007.jpg"/></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiviral properties.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-pharmaceuticals-13-00343" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;-copaene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3&#x02013;6.5%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(1R,2S,6S,7S,8S)-8-isopropyl-1,3-dimethyltricyclo[4.4.0.02,7]dec-3-ene<break/>
<inline-graphic xlink:href="pharmaceuticals-13-00343-i008.jpg"/><break/> C<sub>15</sub>H<sub>24</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhances mating in male Mediterranean fruit flies; Lures for trapping Redbay ambrosia beetle (<italic>Xyleborus glabratus</italic>).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B24-pharmaceuticals-13-00343" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceuticals-13-00343" ref-type="bibr">25</xref>] </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;-selinene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3&#x02013;5.0%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7-Epi-alpha-Selinene<break/>
<inline-graphic xlink:href="pharmaceuticals-13-00343-i009.jpg"/><break/> &#x003b1;-selinene<break/> C<sub>15</sub>H<sub>24</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insecticidal: retarding the growth of mosquito larvae. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-pharmaceuticals-13-00343" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;-terpineol </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;2%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2-(4-methylcyclohex-3-en-1-yl)propan-2-ol<break/>
<inline-graphic xlink:href="pharmaceuticals-13-00343-i010.jpg"/><break/> C<sub>10</sub>H<sub>18</sub>O</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antifungal effects; preservative for the postharvest storage of grapes and other fruits; has been shown to suppress the production of inflammatory mediators when sourced from Tea tree oil.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B26-pharmaceuticals-13-00343" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-13-00343" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">terpinene-4-ol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8&#x02013;1.4%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4-methyl-1-propan-2-ylcyclohex-3-en-1-ol<break/>
<inline-graphic xlink:href="pharmaceuticals-13-00343-i011.jpg"/><break/> C<sub>10</sub>H<sub>18</sub>O</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spasmolytic activity; anti-inflammatory properties have been characterized in constituent isolated from <italic>Melaleuca alternifolia</italic>. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceuticals-13-00343" ref-type="bibr">28</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>* IUPAC names were obtained from <uri xlink:href="https://pubchem.ncbi.nlm.nih.gov/compound/">https://pubchem.ncbi.nlm.nih.gov/compound/</uri>; Chemical structures were obtained from <uri xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</uri>.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceuticals-13-00343-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-13-00343-t002_Table 2</object-id><label>Table 2</label><caption><p>Antibacterial activity of M&#x00101;nuka oil.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Organism</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Method of Analysis</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">%(vol/vol) (&#x000b5;g/mL)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Relevance</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Ref.</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><sup>#</sup> MIC</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">* MBC</th></tr></thead><tbody><tr><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Gram positive bacteria</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Atopobium vaginae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal infections, pre-term birth and neonatal infections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-pharmaceuticals-13-00343" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Bacillus subtilis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intestinal bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-pharmaceuticals-13-00343" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Bacteroides vulgatus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal infections, pre-term birth and neonatal infections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-pharmaceuticals-13-00343" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Lactobacillus plantarum</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral probiotic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-pharmaceuticals-13-00343" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H<sub>2</sub>O<sub>2</sub>-producing <italic>lactobacilli and</italic> non H<sub>2</sub>O<sub>2</sub>-producing <italic>lactobacilli</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.075</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.075</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-pharmaceuticals-13-00343" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Listeria monocytogenes</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-fold serial dilution </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.414</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foodborne pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-pharmaceuticals-13-00343" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Gardnerella vaginalis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal infections, pre-term birth and neonatal infections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-pharmaceuticals-13-00343" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Propionibacterium acnes</italic> ATCC 11827</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.055</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acne</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-pharmaceuticals-13-00343" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Propionibacterium acnes</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.211</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acne</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B43-pharmaceuticals-13-00343" ref-type="bibr">43</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Staphylococcus aureus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two&#x02018;-fold serial dilution </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.535</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foodborne pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-pharmaceuticals-13-00343" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>S. aureus</italic> strains</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-fold serial dilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.513</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple clinical manifestations in humans</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-pharmaceuticals-13-00343" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Methicillin-resistant <italic>S. aureus</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Skin infections, pneumonia, sepsis, surgical site infections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-pharmaceuticals-13-00343" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Streptococcus agalactiae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Meningitis; sepsis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-pharmaceuticals-13-00343" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Staphylococcus epidermidis</italic> ATCC 2223</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.40</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acne</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B41-pharmaceuticals-13-00343" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. intermedius</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0581</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foodborne pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-pharmaceuticals-13-00343" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. sorbinus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.048</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-pharmaceuticals-13-00343" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>S. sorbinus</italic> 6715</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96-well liquid culture microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral pathogen</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B38-pharmaceuticals-13-00343" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>S. sorbinus</italic> B13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96-well liquid culture microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral pathogen</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>S. mutans</italic> JC2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96-well liquid culture microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral pathogen</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>S. mutans</italic> ATCC 25175</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-fold microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral pathogen; dental caries</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-pharmaceuticals-13-00343" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vancomycin-resistant <italic>Enterococcus faecalis</italic> (VRE)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0064</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sepsis; infection of open wounds</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B45-pharmaceuticals-13-00343" ref-type="bibr">45</xref>]</td></tr><tr><td colspan="6" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold><italic>Gram negative bacteria</italic></bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Actinobacillus actinomycetemcomitans (now known as Aggregatibacter actinomycetemcomitans) strains Y4, ATCC 29523, 29524, 33384</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96-well liquid culture microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmaceuticals-13-00343" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Escherichia coli</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intestinal bacteria; opportunistic pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-pharmaceuticals-13-00343" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>E. coli</italic> antibiotic and multidrug resistant strains</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-fold microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospital-based infections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-pharmaceuticals-13-00343" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Fusobacterium nucleatum</italic> ATCC 25586 <italic>strains</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Periodontal disease; dental caries</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-pharmaceuticals-13-00343" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>H. pylori</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastritis, gastric ulcers and gastric cancer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B46-pharmaceuticals-13-00343" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Klebsiella pneumoniae spp.</italic> antibiotics and multidrug resistant isolates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospital-based infections; opportunistic pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-pharmaceuticals-13-00343" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Porphyromonas gingivalis</italic> ATCC 33277, W50 and Su63</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96-well liquid culture microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmaceuticals-13-00343" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>P. gingivalis</italic> ATCC 53977</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96-well liquid culture microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmaceuticals-13-00343" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Pseudomonas aeruginosa</italic> antibiotic and multidrug resistant isolates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-fold microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Burn wound infections, sepsis</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B50-pharmaceuticals-13-00343" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Proteus mirabilis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-fold microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1&#x02013;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hospital based infections</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Salmonella typhimurium</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-fold serial dilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00236</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Not reported </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foodborne bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-pharmaceuticals-13-00343" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. flexneri</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-fold serial dilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00653</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foodborne bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-pharmaceuticals-13-00343" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>S. sonnei</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two-fold serial dilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.00697</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Foodborne bacteria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-pharmaceuticals-13-00343" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Serratia marcescens</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Broth microdilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02265;4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Opportunistic pathogen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B35-pharmaceuticals-13-00343" ref-type="bibr">35</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>* MIC: Minimum inhibitory concentration: minimum dose required to inhibit growth of bacteria; <sup>#</sup> MBC: Minimum bactericidal concentration: minimum dose required to kill bacteria.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceuticals-13-00343-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-13-00343-t003_Table 3</object-id><label>Table 3</label><caption><p>Antifungal activity of M&#x00101;nuka oil.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Organism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">* MIC (% <italic>v</italic>/<italic>v</italic>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><sup>#</sup> MFC (% <italic>v</italic>/<italic>v</italic>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Relevance</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Malassezia furfur</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pityriasis versicolor and Pityrosporum folliculitis</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B37-pharmaceuticals-13-00343" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Trichosporon mucoides</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Opportunistic pathogen</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Candida albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Opportunistic pathogen</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Candida tropicalis</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.13</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Opportunistic pathogen</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Candida albicans</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.015</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Candida vulvovaginitis infections</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B53-pharmaceuticals-13-00343" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Candida glabrata</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaginal candidiasis</td></tr></tbody></table><table-wrap-foot><fn><p>* MIC: Minimum inhibitory concentration; <sup>#</sup> MFC: Minimum Fungicidal concentration. Both values were determined using microdilution assays.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pharmaceuticals-13-00343-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-13-00343-t004_Table 4</object-id><label>Table 4</label><caption><p>Antiparasitic or insecticidal effect of M&#x00101;nuka oil.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Organism</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Method</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Lethal Effect</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Significance</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Acaricidal activity</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Dermanyssus gallinae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Contact assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC<sub>50</sub>: 0.02 to 0.03, LC<sub>90</sub>:0.05 to 0.07<break/> LD<sub>99</sub>: 0.10 mg/cm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poultry red mite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-pharmaceuticals-13-00343" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceuticals-13-00343" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>D. farinae</italic>
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Fabricated disc method</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LD<sub>50</sub>: 0.54 &#x003bc;g/cm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">House dust mite</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B20-pharmaceuticals-13-00343" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>D. pteronyssinus</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LD<sub>50</sub>: 0.67 &#x003bc;g/cm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">House dust mite</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Tyrophagus putrescentiae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LD<sub>50</sub>: 1.21 &#x003bc;g/cm<sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stored product mite</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Sarcoptes scabei</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Contact assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LT<sub>50</sub>: 60 min for 5% solution<break/> LT<sub>50</sub>: 30 min for 10% solution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human scabies mites</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B14-pharmaceuticals-13-00343" ref-type="bibr">14</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Drosophila suzukii</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Contact assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.60 &#x003bc;g/mL for males and 1.10 for females</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fruit fly pest</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-pharmaceuticals-13-00343" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Aedes aegypti</italic> (Linnaeus) larvae</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Larvicidal bioassay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LC<sub>90</sub>: 66.62</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Malaria</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-pharmaceuticals-13-00343" ref-type="bibr">21</xref>,<xref rid="B61-pharmaceuticals-13-00343" ref-type="bibr">61</xref>]</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">
<bold>Repellent effects</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Dermanyssus gallinae (De Geer)</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fumigant assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80&#x02013;84%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poultry red mite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-pharmaceuticals-13-00343" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Dermanyssus gallinae</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fumigant assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poultry red mite</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-pharmaceuticals-13-00343" ref-type="bibr">8</xref>,<xref rid="B59-pharmaceuticals-13-00343" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic>Sarcoptes scabei</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fumigant assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human scabies mites</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B14-pharmaceuticals-13-00343" ref-type="bibr">14</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceuticals-13-00343-t005" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceuticals-13-00343-t005_Table 5</object-id><label>Table 5</label><caption><p>Cytotoxicity of M&#x00101;nuka oil in vitro.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cell Line</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Assay</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Test</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">* TC<sub>50</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Control</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RC-37 cells (African green monkey kidney cells)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutral red assay after treatment for 72 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;-pinene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.006%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1% ethanol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-pharmaceuticals-13-00343" ref-type="bibr">68</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RC-37 cells (African green monkey kidney cells)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutral red assay after treatment for 96 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M&#x00101;nuka oil<break/> Leptospermone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0042%<break/> 0.04%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.6% ethanol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B68-pharmaceuticals-13-00343" ref-type="bibr">68</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">THP-1 (monocyte/macrophage cell line)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XTT cell viability assay after 48 h of treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1&#x02013;10% dissolved in DMSO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No toxicity</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DMSO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B37-pharmaceuticals-13-00343" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vero (African green monkey kidney cells)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutral red assay 96 h after treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M&#x00101;nuka oil (0.001% to 1%)<break/> Leptospermone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0042%<break/> 0.04%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1% ethanol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-pharmaceuticals-13-00343" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HUVEC (Human umbilical vein endothelial cells)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cell Titre Assay</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M&#x00101;nuka oil</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~0.4%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No treatment</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B38-pharmaceuticals-13-00343" ref-type="bibr">38</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>* TC<sub>50</sub>; the concentration of drug that reduces the number of viable cells by 50%.</p></fn></table-wrap-foot></table-wrap></floats-group></article>